1 Article

# Beyond vaccination: A Cross-Sectional Study of the importance of Be-

## havioral and Native Factors on COVID-19 Infection and Severity.

- 4 Hani Amir Aouissi <sup>1,\*</sup>, Mostefa Ababsa <sup>1</sup>, Carlos M. Leveau <sup>2,3</sup>, Alexandru-Ionut Petrisor <sup>4,5</sup>, Artur Słomka <sup>6</sup>,
- 5 Mohamed Seif Allah Kechebar 🗓, Jun Yasuhara 💯, Loïc Epelboin 8, 🗓 and Norio Ohmagari 10,11 🗓
- 6 1 Scientific and Technical Research Center on Arid Regions (CRSTRA), Biskra 07000, Algeria; aouissi.amir@gmail.com (H.A.A);
- 7 <u>mostefa.ababsa@gmail.com</u> (M.A); <u>kechebarmohamed@yahoo.fr</u> (M.S.A.K).
- 8 <sup>2</sup>Consejo Nacional de Investigaciones Científicas y Técnicas: Lanús, Argentina; <u>cmleveau@hotmail.com</u>
- 9 <sup>3</sup>Universidad Nacional del Lanús: Lanús, Buenos Aires, Argentina.
- 10 4Doctoral School of Urban Planning, Ion Mincu University of Architecture and Urbanism, 010014 Bucharest, Romania;
- 11 <u>alexandru petrisor@yahoo.com</u>
- 12 <sup>5</sup> National Institute for Research and Development in Tourism, 50741 Bucharest, Romania.
- 13 <sup>6</sup>Department of Pathophysiology, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz,
- 14 85-067 Bydgoszcz, Poland; <a href="mailto:artur.slomka@cm.umk.pl">artur.slomka@cm.umk.pl</a>
- 15 <sup>7</sup>Center for Cardiovascular Research, The Abigail Wexner Research Institute and The Heart Center, Nationwide Children's Hospi-
- tal, Columbus, OH, USA; jun.yasuhara@nationwidechildrens.org
- 17 <sup>8</sup> Infectious and Tropical Diseases Department, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana; epel-
- 18 <u>boincrh@hotmail.fr</u>
- 19 °Centre d'Investigation Clinique (CIC INSERM 1424), Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana.
- 20 10 Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan;
- 21 <u>nohmagari@hosp.ncgm.go.jp</u>
- 22 11 AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
- 23 \* Corresponding author: aouissi.amir@gmail.com (H.A.A); Tel.: +213662387144
- 24 Abstract: The COVID-19 pandemic has a major impact on a global scale. Understanding the innate and lifestyle-related factors
- 25 influencing the rate and severity of COVID-19 is important for making evidence-based recommendations. This cross-sectional
- 26 study aimed at establishing a potential relationship between human characteristics and vulnerability/resistance to SARS-CoV-2. We
- 27 hypothesize that the impact of virus is not the same due to cultural and ethnic differences. A cross-sectional study was performed
- using an online questionnaire. The methodology included a development of a multi-language survey, expert evaluation and data
- analysis. Data was collected using a 13-item pre-tested questionnaire based on a literature review. Data was statistically analyzed
- using the logistic regression. For a total of 1125 respondents, 332 (29.5%) were COVID-19 positive, among them 130 (11.5%) re-
- quired home-based treatment, and 14 (1.2%) intensive care. The significant factors included age, physical activity and health status
- 32 all found to have a significant influence on the infection (p < 0.05). The severity of infection was associated with preventive
- 33 measures and tobacco (p < 0.05). This suggests the importance of behavioral factors compared to innate ones. Apparently, the indi-
- 34 vidual behavior is mainly responsible for the spread of the virus. Adopting a healthy lifestyle and scrupulously observing preven-
- 35 tive measures including vaccination would greatly limit the probability of infection and prevent the development of severe
- 36 COVID-19.

37 **Keywords**: COVID-19; vaccines; public health; preventive measures; behavior; infectious diseases.

## 1. Introduction

51 1.1 Background

48 49

50

- 52 According to the WHO (World Health Organization), several coronaviruses (CoVs) have been reported since 2002.
- The coronavirus responsible for the 2019 pandemic was named SARS-CoV-2 by ICTV (International Committee on 53
- 54 Taxonomy of Viruses) due to its similarity to SARS viruses [1].
- In the end of 2019, a novel beta coronavirus was identified in China's Hubei province, at Wuhan [2]. By that time, the 55
- virus has spread and disrupted all aspects of humans worldwide. The symptoms of severe acute respiratory syn-56
- drome coronavirus 2 are similar to those of previously known coronavirus infections including fever, dry cough, and 57
- fatigue; however, the SARS-CoV-2 has a higher spreading nature [3,4]. It has largely surpassed MERS and SARS in 58
- terms of both spatial range of epidemic areas and number of infections. The global health crisis experienced has posed 59
- a significant threat to public health [5]. 60
- According to the WHO's weekly operational update on COVID-19 of 13 December 2021, there are almost 273 million 61
- confirmed cases and 5,34 million related deaths worldwide [6]. The consequences were serious, especially at the start 62
- of epidemic, given the lack of information and means to fight this virus [7]. Across the world, a significant number of 63
- proactive measures have been adopted, including distance education, banning international traveling, and the cam-64
- paign encouraging everyone to "stay at home" [8]. Given the unknown and unexpected aspect of this epidemic in 65
- modern times, there is inescapably a lack of research on its psychosocial effects [9]. 66
- Several remedies have been proposed over time to try to eradicate this virus, or limit its spread. The most famous 67 examples are Chloroquine (CQ) and Hydroxychloroquine (HCQ) with or without Azithromycin, still used today as 68
- 69 the last alternative in some countries [10-12]. Other notable examples of proposed remedies include Remdesivir
- [13,14], Favipiravir [15], Dexamethasone [16], Artemesnin [17] and Ivermectin [18]. Actually, as many clinical trials are 70
- still repurposing existing drugs [19]. Since the publication of the genetic sequence of SARS-CoV-2, the whole world 71
- has actively started trying to produce vaccines [20,21]. At present, out of a total of 8,65 billion administrated doses, 72
- more than 3,63 billion people are already fully vaccinated, representing more than 46.6% of the world population [22]. 73
- 74 Each of the vaccines administered worldwide, actually has been subject to specific studies: Johnson & Johnson [23,24],
- 75 Pfizer/BioNTech [25,26], Moderna [27,28], AstraZeneca [29,30], and Sputnik V [31,32]. China has around fifteen vac-
- 76 cines. In addition to being the first developed, they are the most numerous ones [33,34]. The most famous are CanSino
- 77 [35], Sinopharm [36], and finally Sinovac [37]. The latter, in particular, was subject to very complete studies; the first
- 78 one demonstrated that this vaccine effectively prevented the virus, including severe disease and death [38]. The se-
- 79 cond one compared the effectiveness of this vaccine to Alpha and Delta variants, and demonstrated only a meager
- difference in vaccination effectiveness with the Delta variant compared with the Alpha variant after the receipt of two 80
- vaccine doses [39]. The third one showed low efficacy against the omicron variant [40]. The possibility of mixing sev-81
- eral vaccines is also being considered [41]. Currently, the possibility of a fourth dose is considered in some countries 82
- especially since the appearance of the Omicron variant [42]. 83
- Understanding the innate and lifestyle-related factors on the incidence and severity of COVID-19 is critical for making 84 85 appropriate recommendations to prevent the transmission of COVID-19 as well as the development of severe
- COVID-19. However, the detailed characteristics influencing the rate and severity of COVID-19 is not fully under-86
- stood. Previously, the published studies were mainly interested in the influence of COVID-19 on the changes of life-87
- style and not the opposite [43,44]. So far, the COVID-19 questionnaires related much more to the perception of people 88
- 89 concerning this epidemic [45]. Since the epidemic had occurred, several international questionnaires were created.
- 90
- Their purpose was to answer specific question, e.g., about the knowledge and attitude of residents in the prevention
- and control of COVID-19 [2], or the preventive practices against COVID-19 pandemic in the general population [46]. 91
- They were about the mental health impact on people with and without depressive, anxiety, or obsessive-compulsive 92 93
- disorders [47], eating habits, activity and sleep behavior [48], etc. Others focused on particular countries like China
- 94 [49], USA [50], and France [51]. Herein, we conducted a cross-sectional analysis to evaluate the influence of innate and
- lifestyle characteristics on COVID-19 by using an online questionnaire based on the literature review as follows. 95
  - 1.2. Literature review on the main risk factors

96 97

A comprehensive literature review using databases and search engines, such as the Web of Science, Google Scholar, 98 PubMed, and Scopus, was carried out to acquire a global overview of the relationships between the different risk factors and COVID-19. The following keywords: "coronavirus", "COVID-19", "questionnaire", "survey", "tobacco",
"alcohol", "lifestyle", "behavior", "immunity", "ethnic origin", "continent", "country", "epidemic", "blood group",
"sports activity", "age", "educational attainment" and "preventive measures" were included in our search. The search
yielded more than 201 related articles. Furthermore, after screening the titles, abstracts, and full contents, approximately 170 articles were found relevant. 64 were used in the literature review.

The literature review allowed for identifying the risk factors described in the introduction. The conclusion of several studies has amply demonstrated that changes in individual factors would directly (or indirectly) affect the spread of virus. Through literature review and expert opinion, some factors were found to be determinant, e.g. age, social distancing, air temperature, ventilation/airflow, humidity, population density, and community consciousness. These factors were interdependently found to have a strong impact on the SARS-CoV-2 epidemic characteristics [52,53].

111

1.2.1 Tobacco

105

106

107

108 109

110

112

123

124

125 126

127

128

129

130

131

132

133

According to the WHO, tobacco is one of the main causes of premature death and morbidity. It is known that smok-113 114 ing and consuming smokeless tobacco (SLT) products significantly increases the risk of NCDs (non-communicable 115 diseases). According to Islam and Walton [54], only few studies had investigated the relationship between tobacco consumption and COVID-19 [55]. Some of them have showed that the hospitalization rate of smokers is higher than 116 that of non-smokers [56,57]. Berlin et al. [58] encouraged stopping smoking and repeated gestures that facilitate con-117 tamination, and called for the awareness of health authorities. Mistry et al. [59], in their study, found an increased risk 118 of mortality specifically for people over 65, especially those who live in urban areas, because they are exposed to pol-119 lution. Yingst et al. [55] stated that that the increased stress can be detrimental, and it is imperative to create innova-120 121 tive methods to support users interested in quitting during this particularly difficult period.

122 1.2.2 Alcohol

Alcohol consumption increases the risk of community-acquired infections [60]. Nonetheless, news and media showed that the false propaganda of racketeers misled the public into believing that, since alcohol can remove viruses, its consumption can destroy the coronaviruses after entering the body, supposedly because ethanol is commonly used for hand sanitizers [61], but inescapably this is nothing more than a myth. Some studies demonstrated that alcohol poisoning, which is a consequence of the increase in alcohol consumption, increased significantly especially with the appearance of SARS-CoV-2 epidemic [62,63]. In most communities, alcohol poisoning is responsible for several health issues although it can easily be avoided [64]. The availability of methanol and ethanol in recent years led to an augmentation of morbidity and mortality due to alcohol poisoning in some low-income countries, specifically the Muslim ones [65]. Lassen et al. [66] demonstrated that weekly alcohol consumption is associated with the progression to ARDS during hospitalization with COVID-19, but there is a huge lack of studies dealing with alcohol consumption and infection by SARS-CoV-2.

1.2.3 Physical activity

Regular sports activity is associated with a decrease of 6.0% to 9.0% of the risk of influenza-associated mortality [67]. 135 It was demonstrated previously, through a study on mice that exercise (moderately) in the first days after an influenza 136 virus infection, that the mortality was reduced [68]. However, it remains unclear how the physical exercise affects 137 infections. Endurance exercise that lasts less than 1 hour stimulates NK cell cytotoxicity [69]. Moreover, mild physical 138 activity may boost the immune system, whilst exhausting exercise may weaken it [70]. In general, an unhealthy life-139 140 style could have negative consequences, whether dealing with the virus now or in the post-COVID-19 period, specifically in sedentary people. The consequences that a sedentary situation can cause and which we can observe over time 141 are, inexorably, cardiovascular diseases, like obesity, diabetes, hypertension, and metabolic syndrome, because a de-142 143 crease in activity is logically associated with a reduction in insulin sensitivity according to Narici et al. [71]. The same authors claimed that inactivity during confinement could result in a reduction of cardiac volume, oxygen absorption 144 145 capacity, and VO2max (maximum oxygen consumption). A reduction in VO2max and the absorption capacity of oxygen (O2) is often associated with a high mortality rate. In addition, this decrease affects blood circulation and the 146 oxidative function of muscles. In these circumstances, sports activity can be defined as a key strategy to fight against 147 148 unhealthy lifestyle during the pandemic or even after [72] since it contributes to maintaining an optimal state of health (mental/physical). The WHO proposed many general recommendations for sports activity to combat the confinement 149 situation. It consists of performing 150 min or at least 75 min/week of physical activity (moderate or vigorous). It is 150 also recommended to combine activities of different intensities [73]. 151

The majority of studies reported that group A had an increased frequency amongst SARS-CoV-2 infection risk, and the opposite for group O, which is associated with a decreased frequency and risk of infection [3,74]. However, recent studies have shown neither an association between blood group and COVID-19 infection susceptibility nor between blood group O and a decreased risk of infection [75]. The role of blood group in the infectivity of SARS-CoV-2 and COVID-19 severity requires further studies. The role of ABO type is likely secondary and non-modifiable [76] and, apart from blood groups, other population-dependent antigens distribution may be of importance in the fairly heterogeneous spread of the virus in all the geographic areas [77].

1.2.5 Ethnicity

160

Ethnicity is a complex concept, which can include several multiple dimensions, as it is socially constructed and may be associated with biological attributes, such as skin color [78]. Black, Asian, and minority ethnic communities in the UK made up 36.0% of the critically ill patients with COVID-19 requiring intensive care [79]. This phenomenon is not specific to UK; it turns out that this is usually the case in several countries. There is considerable evidence that the incidence of clinically important diseases is higher in many minority ethnic groups despite the fact that impacts of race/ethnicity are likely to vary in different countries, as underlined by some studies [80,81].

Some meta-analyses were published recently. According to Sze et al. [82], there is a clear confirmation that patients of 167 Asian, Black, and Hispanic ethnicities have an increased probability of being infected with coronavirus, compared to 168 white ethnics. In addition, there is a possibly higher risk of intensive care admission and death in Asians. Their find-169 170 ings should be used by institutions and decision-makers to minimize the exposure to COVID-19 in ethnic minorities. 171 This can be achieved through some measures such as helping them access health care resources quickly, observing ethical standards and eliminating as much as possible all forms of racism, social determinism, and inequalities. For Vist et al. [83], even if there is an increased risk of infection and hospital admission due to SARS-CoV-2 for several 173 immigrants and minority ethnic groups, this is especially associated with a low socioeconomic status, resulting into 174 higher admission to hospital and death rates compared to groups with a high socioeconomic status. The fact that may 175 176 explain the tragic situation in some countries compared to others with almost similar ethnicity [84].

177 1.2.6 Gender

Generally, data around the world indicate higher COVID-19 case fatality rates among men than women [85]. Gender-based behavioral and socio-cultural differences may contribute to the sex differences reported in the severity of COVID-19 disease. For example, men wash their hands lesser, especially with soap or other products after entering a restroom, and are more likely to smoke [86].

A large-scale data of two meta-analysis studies demonstrated that despite the fact that there are no significant differences in the proportion of infected individuals with the virus, men are much more likely to develop serious illnesses and die compared to women [87,88] except for some countries like India [89]. According to Bhopal and Bhopal [90], hypotheses based on risk factors that are known to change with both sex and age seem to be the most probable explanations for the observed differences. The differences are due to lifestyle (e.g., alcohol, smoking), occupation, use of medications, or medical co-morbidities. These descriptions reflect cultural and social characteristics associated with gender rather than the biology of sex.

189 1.2.7 Age

Since the beginning of the epidemic, age has been defined as the keystone in COVID-19 infected people [91]. The first data coming from Italy also attested that mortality was highly significant in septuagenarian patients and even higher in octogenarians [92]. A meta-analysis has suggested an essential influence of age on mortality of infected patients with a relevant threshold on age>50 and more especially>60 [93]. This epidemic reminds us daily that older individuals, specifically those with rheumatic diseases [94], are extremely vulnerable to infectious diseases due to co-morbidities linked with age and a decrease in immunological competence or "immunosenescence" [95]. This process, particularly the increased production of inflammatory cytokines resulting from inflammation, is partly responsible for determining the prognosis of COVID-19 in elderly individuals. [96].

The peculiarities of the immune system of older individuals may contribute to both the deficiency of effector mechanisms essential for viral pathogens fighting and an exacerbated inflammatory response, which can accelerate and intensify lung tissue damage [97]. Nonetheless, several authors agree on the fact that one should in no way consider COVID-19 as a "disease of the elderly", but the pandemic should be considered as a temporary setback in a long-term decline in senescent mortality [98].

203 1.2.8 Resistance (immunity)

The genetic background of patients and presence of concomitant pathological conditions were also examined, provided that adaptive immunity to closely related viruses or other microorganisms can reduce susceptibility or increase

the severity of disease [99]. In line with some studies, seemingly most severely affected people have misguided antibodies (autoantibodies) that attack the immune system rather than the virus that causes the disease. A small percentage of the population who develop severe COVID-19 is characterized by a specific genetic mutation that affects immunity. Consequently, many individuals lack effective immune responses, which depend on type I interferon [100,101].

At the same time, it seems that a part of population is more resistant to COVID-19, for example, according to the 211 study by Le Bert et al. [102], some have developed immune cells called T lymphocytes, which are directed against the 212 new coronavirus. This immune response would be "lasting", unlike antibodies, which would disappear quickly. 213 Above all, this response would be present in more than 50.0% of healthy people who have never been infected with 214 the coronavirus. It also demonstrated that different efficacy of both innate and immune responses, according to age 215 and co-morbid conditions, can be a confounding factor [103]. Grasping the combinational and individual role of hosts, 216 217 environmental factors, and viral ones in COVID-19 infection provides a better knowledge of the eventual high-risk groups of people concerning SARS-CoV-2 specifically in terms of severity and susceptibility [104]. 218

## 219 1.2.9 Educational attainment

It has been demonstrated that educational level has an effect on the incidence of some diseases (specifically 220 non-communicable). Low levels of education are related to high prevalence and incidence of cerebrovascular and 221 cardiovascular diseases, cancer, diabetes, hypertension, and chronic respiratory diseases [105]. Generally, a bad soci-222 223 oeconomic status may be linked to low educational level, thus increasing the risk of previously mentioned diseases 224 [106], and of COVID-19 because of low levels of immune cells and high levels of Cytokines in body fluids [107]. It 225 should be remembered that the access to education is not the same elsewhere; when examining urban versus rural outcomes in COVID-19, the disparities are markedly evident when considering county-level data [108]. Concerning 226 the relationship between COVID-19 and educational level, it is acknowledged that education and engagement in 227 health behaviors are positively associated [109], and low education is associated with unhealthy behaviors [110]. 228 229 However, several external factors may be examined and additional measures will have to be studied each time to test for this relationship [111]. Some studies have also suggested that a standardized measurement should be used in fu-230 ture studies [112]. 231

## 232 1.2.10 The continent of residence

As a pandemic, COVID-19 had hit almost every country on earth. Different approaches to emergency management were adopted in each country [113] as in East Asia [114]. Some studies analyzed the differences and similarities in how the inhabitants of different countries responded to government policies enacted during the spread of the COVID-19 pandemic [115] by measuring for example confirmed cases and deaths, the stringency index. The results varied according to each country [116]. If possible, a more government-related response would be worth investigating. Nevertheless, it has been demonstrated that the lag time in responding to government policy and response variability in each country are significantly correlated with the numbers of infections and deaths [117].

## 240 1.2.11 Observance of protective measures

According to the WHO [6], there are many health precautions that individuals can take to avoid COVID-19 infection including frequent hand-washing, wearing facial coverings, maintaining a 2 m distance between themselves and others, staying away from crowds, coughing/sneezing into the elbow (or mask), cleaning/disinfecting surfaces regularly, and examination by a doctor if necessary as recommended by the CDC [118]. In addition, we included vaccination among the strict preventive measures given that at the time when the questionnaire was created, the vaccination process was barely starting and its contribution almost negligible. However, we still have considered it as an additional measure, and discussed in more detail in the introduction.

## 1.3. Aims and importance of research

248

249

257

Given the ambiguity of answers from previous studies that used questionnaires, the present research was designed to correct some past limitations. The aim of this study was to investigate the effects of factors beyond human control (e.g., blood group, ethnicity) on COVID-19 potential infection and severity, and of lifestyle or behavioral characteristics (e.g., tobacco use, sports activity, and alcohol consumption). Based on the fact that the number of infections varies greatly by country and continent (even if this may also be due to significant variations in the level of underreporting of cases between countries), we hypothesized that the innate factors should be the most significant in deciding on the possible infection of individuals. We examined this assumption using questionnaires for quantification.

258 2.1 Overview

268

269

270

271272

273

274

275

276

277

278279

280

281 282

283

288

306

307

308

The present study is based on a cross-sectional design, using an online questionnaire. The main function of questionnaires was to give the survey a greater extension. It was also used as a means to verify statistically the extent of generalization that can be reached by the existent information and preliminary assumptions [119].

To accomplish the aim, we designed an anonymous online survey with a sufficient number of items; its qualities include conciseness, scientific structure, pre-testing and global practicability. Considering the lack of similar works, the questionnaire addressed some basic information and all major lifestyle aspects. To ensure optimal compliance with preventive measures against the spread of virus, we have deliberately chosen to share the survey exclusively online, to limit contact as much as possible. A standardized methodology including steps such as literature review, expert review, ethical approval and pre-testing were undertaken to develop and validate the questionnaire [120,121].

2.2 Development of the questionnaire

We drafted our questionnaire in four languages: Arabic, English, Spanish and French, which are in the top 6 most spoken worldwide, along with Chinese and Hindi [122]. The data was collected via Google Forms, through a self-report questionnaire. Additionally, the questionnaire consisted of three main parts. The first one was related to the socio-demographic characteristics. The second part consisted of items related to behavior, and the last part included the infection status (yes or no) and its severity. We made the questionnaire as easy as possible with a minimum of items, so that it could be understood by almost the entire world population. We have particularly made sure that it is very fast to answer so as not to be discouraging, while deliberately excluding criteria that are too subjective or difficult to measure (e.g., hours of sleep, quality of nutrition, and stress rate). To highlight the importance of research and great credibility, the tool was presented to a committee of national and international experts who helped to improve it by deleting or rewording some items. Their intervention made possible to ensure its suitability and validity before applying it to the participants. Conventionally, the ethical approval and consent were obtained from the CRSTRA and all participants. The questionnaire was shared via social media including Instagram, Facebook, LinkedIn, WhatsApp and volunteer participants were requested to fill in the online form. However, we required that the respondents should be at least 18 years old to answer, and asked for a confirmation for each respondent.

284285 2.3. Statistical analysis

Statistical analyses were performed using SAS® (version 9.4). We coded the contamination factors on a numerical scale due to their nature (nominal or ordinal variable). For this reason, the responses were coded as following:

289 A progressive scale describing the direction of variation concerning the factors of an ordinal nature:

-Educational attainment: 0-3 (0=Not precise, 1= No study or primary, 2= Middle/secondary, 3= University/post-university) - Age: 1-4 (1=18-30, 2= 31-45, 3= 46-59, 4= 60+) - Sports activity: 1-3 (1= Little or no activity, 2= Moderate, 3= Very active) - Health status: 1-3 (1=Resistant, 2= Moderately sensitive, 3= Very sensitive). - Tobacco use: 1-3 (1=No, 2= Occasionally, 3= Frequently) - Alcohol consumption: 1-3 (1=No, 2= Occasionally, 3= Frequently) - Protective measures against COVID-19: 1-3 (1=Not at all, 2= Medium application, 3= Strict application) - Severity: 0-3 (0=Healthy, 1= Low, 2= Treatment, 3= Intensive care).

296 A two-choice scale for the question: "Have you been affected by COVID-19?" (No=0, Yes=1).

A random scale for factors of a nominal nature: - Residence (1=Africa, 2= Europe, 3= North America, 4= South America, 5= Asia, 6= Oceania) - Ethnicity (0= Not precise, 1= Other, 2=African / Afro-American, 3= Caucasian, 4= Arabic, 5= Asian, 6= Latino) - Gender (0=Not precise, 1= Male, 2= Female, 3= Other).

We noticed that the estimations of odds ratios were affected by very small sample size for specific levels of the variables. In order to increase the validity of statistical analyses, data for some levels were removed, by changing them to missing observations: Gender – 3 "Other" values, Continent – 2 "Oceania" values, Health – 1 "0=Healthy" value, Continent – 10 "4=South America" values, and Ethnicity – 11 "6=Latino" values. However, we did not eliminate any blood groups, despite of the reduced sample size influencing in one case the estimation of odds ratios, because it make no sense from a health standpoint.

Two statistical analyses were run:

• The dependence of having been affected before or not by COVID-19 on the potential risk factors investigated was analyzed using logistic regression, a statistical method modeling a binary event as probability of its occurrence.

• The dependence of the severity of infection on potential risk factors investigated was also analyzed using logistic regression, after eliminating healthy subjects from the analysis and turning the "Severity" variable into a binary one, which indicates if the patient needs treatment or intensive care.

Provided that the difference in the odds ratios is not the same for the different levels of the predictors considered in this study, absolutely all independent variables were treated as categorical in all analyses.

Model selection was performed with the intention of finding a model including only predictors with a significant impact on the response when acting together. The model selection was performed using the approach proposed by Collett [123], consisting of: (1) performing univariate regressions with each predictor separately, (2) building a first multivariable model with all predictors if their p-values in (1) were below 0.2; (3) performing a backward elimination with the model obtained in (2), by eliminating the variable with the least influence on the response (indicated by the highest p value), until all variables in the model had a statistically significant influence on the response, and (4) attempting to re-include variables not retained at the end of (3), in order to check if the model quality can be improved.

For all statistical analysis, the level of significance was 0.05. However, since the sample size was not very large, the presentation of results also includes results significant at the 0.1 level. In this case, additional data would probably have led to significant results.

#### 3. Results

324

325

328

329

330 331

332

309

310

311

## 3.1. Descriptive statistics

For a total of 1125 responses, 753 responses (67.0%) were made in French, 225 (20.0%) in Arabic, 135 (12.0%) in English, and finally 12 (1.0%) in Spanish.




Figure 1. Representation of received anwsers

For 1125 respondents, 332 were COVID-19 positive, 130 required home-based treatment, and 14 required an intensive care.

Table 1. Characteristics of the sample study

Characteristics	Answers	Sample	Percentage %
	Africa	963	85.6%
	Europe	83	7.4%
Continent of week dames	North America	19	1.7%
Continent of residence	South America	10	0.9%
	Asia	48	4.3%
	Oceania	2	0.2%

	Not precise	13	1.2%
	Other	98	8.7%
	African / Afro-American	126	11.2%
Ethnic origin	Caucasian	61	5.4%
	Arabic	794	70.6%
	Asian	22	2.0%
	Latino	11	1.0%
	not precise	7	0.6%
	Male	394	35.0%
Gender	Female	<b>72</b> 1	64.1%
	Other	3	0.3%
	18-30 years	727	64.6%
	31-45	315	28.0%
Age	46-59	60	5.3%
	60	23	2.0%
	not precise	13	1.2%
	A+	344	30.6%
	A-	21	1.9%
	B+	163	14.5%
Blood group	В-	17	1.5%
	AB+	56	5.0%
	AB-	8	0.7%
	O+	471	41.9%
	O-	32	2.8%
	Not precise	0	0.0%
	No study or primary	67	6.0%
Educational attainment	Middle or secondary	236	21.0%
	University or post-university	820	73.0%
	Little or no activity	557	49.6%
Sports activity	Moderate	451	40.2%
	Very active	114	10.2%
	Resistant (little or no flu / colds)	730	65.3%
Health status	Moderately sensitive (regularly subject to flu / colds)	331	29.6%
	Very sensitive (suffering from chronic disease (s) or others)	57	5.1%
	No	962	85.7%
Tobacco use	Occasionally	83	7.4%
	Frequently	78	6.9%
	No	1025	91.4%
Alcohol Consumption	Occasionally	81	7.2%
	Frequently	16	1.4%
	Not at all	65	5.8%
Observance of protective measures	Medium application	649	57.7%
	Strict application	411	36.5%

Infection with COVID-19	No	790	70.4%
	Yes	332	29.6%
Infection state	Healthy (no infection)	802	71.3%
	Low (no special care)	179	15.9%
	Treatment and /or care	130	11.6%
	Intensive care	14	1.2%

3.2. Data analysis

Table 2 presents an overall image of analyses looking at the influence of considered predictors on the infection with COVID-19 and its severity. For each of the two, the table displays three models in separate columns. The first one looks at the individual relationship between the infection with COVID-19 and its severity with each predictor. The second column presents a "full model", ascertaining the simultaneous influence of all predictors on the infection with COVID-19 and its severity. Finally, the third column presents a "prediction model", resulted from the full one, and containing only predictors with a significant influence on the infection with COVID-19 and its severity, when considered simultaneously. The table clearly shows that age, sports and health status were significantly associated with the infection with COVID-19, whereas tobacco and protection were significantly associated with its severity.

**Table 2**. Analysis of the influence of considered predictors on the infection with COVID-19 and its severity. The table describes the influence, separately (column labeled "Univariate"), the simultaneously (column labeled "Full model") and a final model resulting from selection including only predictors with a statistically significant simultaneous influence (column labeled "Selected model").

**Bold** values indicate a statistically significant impact (p≤0.05), and those in *Italic* a marginally significant impact (0.05<p≤0.1).

Influence	Dependent variable								
(Model)		Infection	L		Severity				
(Model)	Univariate	Full model	Selected model	Univariate	Full model	Selected model			
Continent	0.3949	0.0891		0.2074	0.0888				
Ethnicity	0.3217	0.1553		0.9307	0.6429				
Gender	0.1654	0.7951		0.1088	0.7922				
Age	0.0027	0.0185	0.0019	0.4958	0.6296				
Blood	0.0667	0.1869		0.4963	0.4590				
Education	0.2661	0.5919		0.6485	0.6156				
Sports	0.0009	0.0010	0.0005	0.1478	0.2808				
Health	0.0032	0.0919	0.0118	0.0723	0.1300				
Tobacco	0.0934	0.6743		0.0164	0.3364	0.0370			
Alcohol	0.1483	0.7615		0.1589	0.3068				
Protection	0.4519	0.4083		0.0004	0.0042	0.0015			

Having been affected or not by COVID-19 was analyzed via logistic regression whose results are presented in Table 3. The model was overall significant (p < 0.0001). The logistic regression demonstrated that age, sports activity and health status showed significant impacts on the infection of COVID-19.

**Table 3**. Results of the logistic regression showing the factors determining whether a subject has been affected by COVID-19 or not. **Bold** values indicate a statistically significant impact ( $p \le 0.05$ ), and those in *Italic* a marginally significant impact (0.05 ). The model includes all analyzed factors.

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				Africa vs. North America	0.355	0.013	9.687
Continent	3	6.5147	0.0891	Asia vs. North America	0.691	0.014	34.708
				Europe vs. North America	2.781	0.083	92.650
				Other vs. Asian	2.790	0.222	35.031
				African /			
				Afro-American vs.	2.198	0.154	31.419
Ethnicity	4	6.6549	0.1553	Other			
				Caucasian vs. Asian	9.962	0.571	173.918
				Arabic vs. Asian	4.956	0.369	66.604
Gender	1	0.0674	0.7951	Male vs. Female	1.089	0.571	2.076
				18-30 vs. 60+	13.133	1.238	139.335
Age	3	10.0082	0.0185	31-45 vs. 60+	4.112	0.413	40.952
				46-59 vs. 60+	3.485	0.293	41.460
				A+ vs. O-	3.081	0.638	14.887
				A- vs. O-	<0.001*	<0.001*	>999.999*
				B+ vs. O-	1.192	0.224	6.338
Blood	7	10.0299	0.1869	B- vs. O-	4.288	0.125	147.175
				AB+ vs. O-	9.939	1.106	89.323
				AB- vs. O-	0.474	0.010	22.533
				O+ vs. O-	2.720	0.569	12.987
				No study or			
				primary vs. University/	1.401	0.514	3.820
Education	2	1.0488	0.5919	post-university Middle/ secondary			
				vs. University/	1.535	0.597	3.947
				post-university	1.555	0.577	3.747
				Little or no			
				activity vs. Very	2.729	0.978	7.620
Sports	2	13.7657	0.0010	active	2.729	0.570	7.020
- r	_			Moderate vs. Very	0.941	0.346	2.559
Health	2	4.7731	0.0919	Resistant vs. Very	4.078	1.069	15.559
1 1011111	4	1.7701	0.0313	10000min vo. very	1.070	1.000	10.000

Variable	DF	Wald Chi-Square	p-value	Level	OR Estimate	95% Lower Wald Confidence Limit	95% Upper Wald Confidence Limit
				sensitive			
				Moderately sensitive vs. Very sensitive	3.007	0.769	11.763
				No vs. Frequently	0.647	0.191	2.189
Tobacco	2	0.7881	0.6743	Occasionally vs. Frequently	0.531	0.131	2.155
				No vs. Frequently	0.683	0.077	6.035
Alcohol	2	0.5448	0.7615	Occasionally vs. Frequently	0.460	0.041	5.129
				Not at all vs. Strict application	1.629	0.546	4.859
Protection	2	1.7915	0.4083	Medium			
				application vs.	1.462	0.815	2.622
				Strict application			

<sup>\*</sup>The estimates are unusually large, because in reality they exceed the program thresholds. This happens because of the very low sample size for specific levels (groups). While some were eliminated from the analysis (e.g., Gender – 3 "Other" values, Continent

Since not all factors in Table 3 were found to exert a statistically significant influence on having been affected or not by COVID-19, model selection was run in order to identify a model where all factors significantly affect the probability of having been affected or not by COVID-19. The model resulted by eliminating, in this order, the variables tobacco, gender, education, blood, and ethnicity. The resulting model, significant at p < 0.05, is displayed in Table 4.

**Table 4**. Results of the logistic regression showing the factors determining in a statistically significant way whether a subject has been affected by COVID-19 or not. All factors have a statistically significant impact ( $p \le 0.05$ ). Some levels were eliminated from the analysis (e.g., Gender – 3 "Other" values, Continent – 2 "Oceania" values, Health – 1 "0=Healthy" value, Continent – 10 "4=South America" values, and Ethnicity – 11 "6=Latino" values), but it did not make sense eliminating a blood group, for medical reasons.

Variable	DF	Wald	l	p-value Level	OR	95% Lower Wald	95% Upper Wald
variable	Dr	Chi-Square	p-value	Level	Estimate	Confidence Limit	Confidence Limit
				18-30 vs.	10.841	1.247	94.234
				60+	10.041	1.24/	
Age 3	14.8694	0.0010	31-45 vs.	4.707	0.531	41 522	
	3	14.8694	0.0019	60+	4.707	0.551	41.732
				46-59 vs.	3.940	0.377	41.199
				60+			41.177
				Little or no		1.192	6.668
				activity vs.	2.820		
Sports	2	15.3573	0.0005	Very active			
Sports	۷	13.3373	0.0005	Moderate			
				vs. Very	1.037	0.448	2.400
				active			
Health	3	8.8880	0.0118	Resistant	5.158	1.587	16.763

sample size for specific levels (groups). While some were eliminated from the analysis (e.g., Gender – 3 "Other" values, Continent – 2 "Oceania" values, Health – 1 "0=Healthy" value, Continent – 10 "4=South America" values, and Ethnicity – 11 "6=Latino" values),

it did not make sense eliminating a blood group, for medical reasons.

vs. Very			
sensitive			
Moderately			
sensitive vs.	3.384	1.010	11.337
Very	3.304	1.010	11.55/
sensitive			

The dependence of the severity of infection on potential risk factors investigated was analyzed using the logistic regression. The results are presented in Table 5. The model was overall significant (p = 0.0201). Here, the respect of protective measures and smoking were significantly associated with the severity of infection.

Table 5. Results of the logistic regression showing the factors determining whether a subject has been severely affected by COVID-19 or not. Variables with names written in **Bold** have a statistically significant impact, and those in *Italic* a marginally significant impact (0.05<p≤0.1). The model includes all analyzed factors. Some levels were eliminated from the analysis (e.g., Gender – 3 "Other" values, Continent – 2 "Oceania" values, Health – 1 "0=Healthy" value, Continent – 10 "4=South America" values, and Ethnicity – 11 "6=Latino" values), but it did not make sense eliminating a blood group, for medical reasons.

Variable	DF	Wald	1	Level	OR	95% Lower Wald	95% Upper Wald
v ariable	DF	Chi-Square	p-value	Level	Estimate	Confidence Limit	Confidence Limit
				Africa vs. North	0.531	0.156	1.803
				America	0.551	0.136	1.000
Continent	3	6.5229	0.0888	Asia vs. North	1.339	0.303	5.916
Continent	J	0.3223	0.0000	America	1.555	0.505	5.910
				Europe vs. North	0.966	0.255	3.654
				America	0.300	0.233	J.0J <del>4</del>
				Other vs. Asian	1.873	0.593	5.916
				African /			
				Afro-American	1.568	0.497	4.953
Ethnicity	4	2.5095	0.6429	vs. Other			
				Caucasian vs.	1.167	0.336	4.050
				Asian	1.107	0.550	4.000
				Arabic vs. Asian	1.756	0.582	5.299
Gender	1	0.0694	0.7922	Male vs. Female	0.957	0.690	1.327
				18-30 vs. 60+	1.450	0.539	3.899
Age	3	1.7330	0.6296	31-45 vs. 60+	1.199	0.455	3.162
				46-59 vs. 60+	0.986	0.330	2.949
				A+ vs. O-	1.465	0.643	3.341
				A- vs. O-	5.754	1.067	31.035
				B+ vs. O-	1.655	0.695	3.944
Blood	7	6.7163	0.4590	B- vs. O-	3.469	0.624	19.265
				AB+ vs. O-	2.032	0.734	5.626
				AB- vs. O-	1.575	0.241	10.299
				O+ vs. O-	1.422	0.630	3.209
				No study or			
Education	2	0.9703	0.6156	primary vs.	0.946	0.538	1.664
				University/			

Variable	DF	Wald	p-value	Level	OR	95% Lower Wald	95% Upper Wald
Vulluble		Chi-Square	p varae	Level	Estimate	Confidence Limit	Confidence Limit
				post-university			
				Middle/			
				secondary vs.	1.250	0.767	2.035
				University/	1.200	0.7 07	2.000
				post-university			
				Little or no			
				activity vs. Very	0.968	0.585	1.603
Sports	2	2.5403	0.2808	active			
				Moderate vs.	0.777	0.470	1.283
				Very active	01777	0117 0	1.200
				Resistant vs.	1.273	0.691	2.345
				Very sensitive	1.2.	0.007	2.0.10
Health	2	4.0803	0.1300	Moderately			
				sensitive vs.	0.943	0.502	1.772
				Very sensitive			
				No vs.	0.985	0.550	1.765
Tobacco	2	2.1788	0.3364	Frequently			
				Occasionally vs.	0.673	0.331	1.368
				Frequently			
				No vs.	1.864	0.550	6.324
Alcohol	2	2.3629	0.3068	Frequently			
				Occasionally vs.	1.243	0.334	4.631
				Frequently			
				Not at all vs.			
				Strict	0.387	0.210	0.715
				application			
Protection	2	10.9263	0.0042	Medium			
				application vs.	0.700	0.517	0.947
				Strict			
			application				

Since not all factors in Table 5 were found to exert a statistically significant influence on the severity of COVID-19 infection, model selection was run in order to identify a model where all factors had a significant influence. The model resulted by eliminating, in this order, the variables gender, education, ethnicity, tobacco, blood, sports, continent, and age. The resulting model, significant at p < 0.05, is displayed in Table 6.

Variable	DF	Wald	p-value	Level	OR	95% Lower Wald	95% Upper Wald
v allable	DI	Chi-Square	p-value	Level	Estimate	Confidence Limit	Confidence Limit
			No vs.	0.983	0.589	1.641	
Tobacco	2	6.5963	0.0370	Frequently	0.963	0.369	1.041
Tobacco	Tobacco 2 6	0.3903		Occasionally vs.	0.539	0.539 0.280	1.040
				Frequently			1.040
		13.0085	0.0015	Not at all vs.	0.382	0.220	0.662
				Strict application		0.220	0.663
Protection	2			Medium			
				application vs.	0.725	0.547	0.961
				Strict application			

#### 4. Discussion

4.1 Significance of the results and health recommendations

In this cross-sectional study, we evaluated association between innate and lifestyle-related factors on the rate and severity of COVID-19. The main findings are as follows: 1) age, physical activity, and health status were found to have a significant influence on the infection of COVID-19; 2) observance of preventive measures and tobacco consumption had a significant influence on the severity of the infection of COVID-19.

We confirmed the significant influence of the following factors on the possibility of infection: age, sports activity and to a lesser degree health status. We could thus interpret the factors on the rate of infection is by the fact that the older the person is, the more the individual will be subject to the infection, and this is confirmed with the positive wideness of the estimated parameter of the logistic regression, thus agreeing with previous studies [93,95]. With regard to physical activity, our results showed that the more active the individual, the less likely he is to be infected with the virus, this was also confirmed by the positive wideness of the estimated parameter of the logistic regression and agreeing with the previous studies [71,73]. While for the health status, the estimated parameter indicates that the more the individual's sensitivity increases, the more the individual will be subject to infection, only confirming the results of previous studies concerning immunity [102]. Our results indicate that the compliance with preventive measures is essential. It seemed obvious to remind each time to observe the protective measures (wearing the mask, quarantine, remote working, hygiene, vaccination, etc.). The problem is that the average population thinks that after being vaccinated it is no longer mandatory to apply preventive measures [124]. It is true that previous studies have shown that vaccination of health care workers was associated with a substantial reduction in infections [125] or that one dose of vaccine reduces the potential for transmission by 61.0% [126], but the contamination possibility still exists. We encourage media and public health organizations to clarify this information [127].

In the same vein as for the probability of infection, it would seem for the severity that the more an individual smokes, the more severe his infection will be and will in most cases lead to hospitalization thus confirming the logic of previous work [56,57]. With regards to protective measures, the logistic regression showed that the more the individual was strict in his application of the preventive measures promoted by the WHO and CDC [118], the less likely he will have a severe infection if he was infected. A previous online questionnaire observational study demonstrated that the use of protective measures was not associated with symptom severity of COVID-19 [128]. Another South Korean study showed that preventive measures had a negative influence on cardio metabolic profiles in subjects with metabolic impairments [129]. To our knowledge, there has not been any work that has demonstrated the positive effect of preventive measures on COVID-19. In contrast, a study in Pakistan showed that the application of protective measures dramatically reduces the risk of other respiratory diseases [130] Recently a Japanese study focused only on wearing a mask as a measure and they found that for a sample of 820 individuals, mask users were infected at a rate of 0.4 times

that of those who did not wear masks [131] demonstrating the importance of this measure. Our findings provide novel insights into the role of personal protective measures on the spread of infection and symptom severity. Further study is warranted to confirm our findings.

Regarding age, since the beginning this pandemic, COVID-19 has always been associated with old individuals [132].
A higher need for intensive care increase by age among individuals older than 45 years [133]. Our findings only confirm the importance of this factor by going in the same direction as previous reviews and meta-analysis studies [134,135].

Concerning alcohol, the situation is a little paradoxical. Our findings showed that the alcohol consumption has no significant influence on the probability of infection and its severity. However, Abbasi-Oshaghi et al. [136] found the opposite, because long-term drinking is closely related to zinc and vitamin deficiency. Hikida et al. [137] also found out that alcohol probably increases the risk of exposure to and morbidity from COVID-19. In addition, according to the same study, alcohol consumption is associated with prosecution and having regrets, which can increase the severity of COVID-19. González-Reimers et al. [138] discussed the fact that it has already been proven that various chronic disorders may increase the risk of pneumonia (and by extrapolation COVID-19) severity. Precisely for the severity, a Chinese study performed on more than 1,500 patients claimed that the severity of infection was greater in patients who consume alcohol regularly or with a history of consumption [139]. At the same time, a recent review article also confirmed that alcohol consumption adds vulnerability to patients and leads to an increased severity of COVID-19 and other long-term health problems [140]. Nevertheless, others remain a little less categorical leaving doubt by pointing out the influence of several factors at the same time as well as the need for further studies [141,142].

While for tobacco, the results of our work are quite logical because it was more associated with the severity of infection compared to the infection. Indeed, non-smokers are obviously not immune to the virus; however, smoking patients are vulnerable to severe COVID-19 [143]. This perfectly confirms the findings of previous studies [144,145].

In general, the measures must be subject to a special focus especially for sensitive sectors. Citing as an example the education sector, where the application of measures was investigated in a few articles [146,147] but the most striking example remains, as stated previously, the health sector [148,149]. We think that it is important for each individual to educate about his own health on a regular basis. This issue remains debatable, as in many countries the relationship between educational disparities and socioeconomic status is discussed a lot without reaching a final answer [150,151]. Variability in immune system components (innate) is a major contributor to the heterogeneous disease courses noticed for Sars-CoV-2 [152]. The immune response differs from a person to another and should not be relied on in any way provided the still unknown character of several mechanisms [153]. A continuous effort to understand all mechanisms, especially those concerning host-virus interactions, is essential to overcome the pandemic [154]. In our study, a health state was associated with a reduced probability of contracting the virus, which can demonstrate the importance of innate immunity, but in no case should we be totally based on this. Nevertheless, we cannot limit human health solely to these factors, and the effectiveness of vaccine plays the most important role. Further studies are needed to confirm the relationship between vaccines, pollution, and their consequences [155].

A point not to be overlooked concerns the sources of information (or disinformation). A recent study on Jordanian and Iraqi participants revealed that more than half of the population of the two countries use social media as the most common COVID-19 information source, sharing a lot of false information which may lead to gaps in the actions to be adopted [156]. A cross-sectional study conducted in Saudi Arabia focused on testing the knowledge of residents with questions about the measures to be taken, and more than 90.0% of the population was above average by specifying in particular that people with a low level of education have failed [157]. Still in the same country, the observance of precautionary measures among nursing staff was studied, and results show that a high number (71.2%) were competent and less qualified personnel should nevertheless be trained in particular [158]. This would be applicable to all countries, and could prove useful.

Finally, our original research goal was to analyze the influence of two groups of factors and their influence on COVID-19 to reduce the spread of the virus. These findings also agree with the WHO reports who have constantly repeated the various protective measures to be taken for avoiding any possible infection and thus indirectly limiting the spread of virus [6]. Additionally, this study is one of only few going against the idea that a part of the world population is automatically condemned to infection because of their ethnicity, place of residence etc. Our study is meant to be encouraging by showing that each person has almost entirely its destiny in its hands as long as a healthy lifestyle is observe and precautions taken; it is also about advising people to self-educate. This can have only positive effects, even in the long term.

The originality of this study comes from the fact that it is the only international study providing more information on the African and Mediterranean areas, carried out in 4 different languages. The number of respondents is quite high and heterogeneous compared to almost all questionnaires presented in previous studies. Moreover, the vast majority of publications have focused on a particular sector [159], a particular region [160] or a well-targeted population [161]. In addition, previous studies dealt with a single characteristic or group of characteristics [162,163], while the present study includes 13 items based on a substantial literature review. These items addressed two groups of characteristics comparing the most significant ones. Everything was simplified as much as possible in order to reach all categories of the world population and collect more information applicable to the vast majority, so that we can encourage them to adopt the right actions to prevent the infection, and ultimately limit the spread of disease. Moreover, the ranked in-fluence of COVID-19 infection drivers has never been evaluated before. Any additional findings are important, pro-vided their possible contribution to the fight against this pandemic. 

## 4.3 Methodological limitations

Our analysis was limited to a number of factors considered as relevant based on the literature review, and which could be ascertained using an online questionnaire. However, different studies also pointed out a number of other potential risk factors.

Objectively, it is an almost impossible challenge to know exactly the factors responsible for infection and transmission of COVID-19. Sources may be incomplete; apart from the factors discussed previously, even the meteorological ones were considered a potential explanation [164]. A study in Korea demonstrated that the environment plays a significant role in the spread of COVID-19, but like any factor, it may have also been impacted by various additional features [165]. Hence, further studies are needed to protect people from COVID-19 transmission, specifically on infection dynamics and the mode of transmission, e.g., cluster spaces, closed spaces, and indoor environments [166].

At the individual level, everyone must take the maximum possible precautions. It should also be remembered that no less than 10 reasons supporting airborne transmission were phrased recently by Greenhalgh et al. [167]. The long-term health consequences of COVID-19 remain unclear and continue to be studied [168]. Therefore, it is preferable to avoid any form of infection, even mild. Another factor that we do not necessarily think about and which may be important is the wastewater treatment and disinfection strategies with chemical products; all demonstrate that we must take into account an incalculable number of factors [169].

We can also mention certain biases concerning the sample. The majority of respondents were young intellectuals from the Arab (and Muslim) world; consequently, tobacco and alcohol remain taboo subjects, so it is possible that some respondents did not tell the truth about these characteristics, and our results could be biased. Integrating vaccination as a protective measure rather than as a factor in its own right when carrying out this sampling was not a limiting factor; time has showed that this is the case now.

### 4.4 Perspectives for future research

Undoubtedly, this study could not explicitly pretend to yield results able to stop this pandemic. In general, making predictions on this virus, which remains unknown, is impossible. Therefore, any additional information may prove useful. We consider that each study on this topic contributes in its own way to fighting indirectly against the pandemic crisis we are currently experiencing. Previously, we have enumerated a certain number of limitations in this work, including the number of answers received to the questionnaire. While this is acceptable, more answers could help obtaining more representative results, and increasing their statistical significance. Future studies should seek to use a larger and even more diverse sample, and include additional recruitment strategies. For example, future studies should include in their sample information provided by parents of children under 18 years old, as they are also a group of high concern given the target specificity of the new virus variants.

## 5. Conclusions

In this study, we found that health status, age and physical activity significantly influence the infection (p < 0.05). The non-respect of preventive measures and smoking tobacco significantly aggravate its severity (p < 0.05). It would also appear that no matter where an individual is, what his/her age is, and everything that characterizes the person from birth, are not ultimately the main characteristics to be taken into consideration concerning the COVID-19 infection (and severity). Despite the limitations, based on our results this is the first study that demonstrated that it would be much more the lifestyle of the individual that decides a potential infection. Therefore, we strongly encourage the world population to adopt a healthy lifestyle: no alcohol, no tobacco, or at least reducing their consumption; eat

- 522 healthily, sleep well and practice regularly a physical activity, in addition to a massive vaccination, specifically for
- 523 medical staff and people at risk. Finally, the capital points not to be neglected will inevitably remain the fact of avoid-
- 524 ing as much as possible any gathering (apply social distancing, in particular by using remote working to the maxi-
- 525 mum extent possible) and observe the protective measures promoted by the WHO. Further studies remain necessary
- to help fighting against the constantly evolving epidemiological situation. In the end, we hope that this positive mes-
- sage that we deliver (supported by results) can positively influence the behavior of people while waiting for the
- health crisis to subside and for the world to return to normality.
- 529 Author Contributions: Conceptualization, H.A.A., M.A. and A-I.P; methodology, H.A.A., M.A. and A-I.P.; validation, C.M.L., L.E.
- and N.O.; formal analysis, H.A.A, A-I.P., L.E. and N.O.; investigation, H.A.A. and M.A.; resources, A.S., M.S.A.K.; data curation,
- 531 M.A and A-I.P., writing—original draft preparation, H.A.A, A-I.P., J.Y. and L.E.; writing—review and editing, H.A.A, A-I.P., A.S.,
- 532 J.Y. and N.O.; visualization, C.M.L., L.E and N.O. supervision, A-I.P, L.E. and N.O.; project administration, M.S.E.K.; funding ac-
- quisition, H.A.A., A.S., and M.S.E.K. All authors have read and agreed to the published version of the manuscript.
- 534 Funding: This research was funded by the DGRSDT and the MESRS.
- 535 **Institutional Review Board Statement**: Not applicable.
- Informed Consent Statement: Informed consent was obtained from all subjects involved in the study and all procedures were approved by the CRSTRA.
- Data Availability Statement: The data generated and/or analyzed in the current study is available from the corresponding author on reasonable request.
- 541 Acknowledgments: Considerable appreciation is addressed to the DGRSDT (Directorate-General of Scientific Research and Tech-
- 542 nological Development of Algeria) and the MESRS (Ministry of Higher Education and Scientific Research of Algeria) for their val-
- uable support. The authors thank, as well, all of the respondents in this study for their voluntary participation and for providing
- 544 such essential information. Many thanks are also addressed to anyone who helped us by sharing the questionnaire.
- Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

#### References

538

547548549

550

551

552 553

554

555

556

557

558

559

560

561 562

563

564

565

566 567

568 569

570

571

572 573

574

575

576

577

- 1. Cui, J.; Li, F.; Shi, ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* **2019**, 17, 181–192. <a href="https://doi.org/10.1038/s41579-018-0118-9">https://doi.org/10.1038/s41579-018-0118-9</a>
- 2. Yang, W.; Sirajuddin, A.; Zhang, X.; Liu, G.; Teng, Z.; Zhao, S.; Lu, M. The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). European radiology 2020, 30(9), 4874–4882. https://doi.org/10.1007/s00330-020-06827-4
- 3. Wu, Y.; Feng, Z.; Li, P.; Yu, Q. Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. *Clin. Chim. Acta* 2020, 509, 220–223. https://doi.org/10.1016/j.cca.2020.06.026
- 4. Yasuhara, J.; Kuno, T.; Takagi, H.; Sumitomo, N. Clinical characteristics of COVID-19 in children: A systematic review. *Pediatr Pulmonol.* **2020**, 55(10), 2565-2575. <a href="https://doi.org/10.1002/ppul.24991">https://doi.org/10.1002/ppul.24991</a>
- 5. Deng, S. Q.; Peng, H. J. Characteristics of and public health responses to the coronavirus disease, outbreak in China. *J. Clin. Med.* **2020**, *9*, 575. <a href="https://doi.org/10.3390/jcm9020575">https://doi.org/10.3390/jcm9020575</a>
- 6. World Health Organization. Novel coronavirus (2019-nCoV) situation reports. Available from: <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</a> 2021.
- 7. Van Damme, W.; Dahake, R.; Delamou, A.; Ingelbeen, B.; Wouters, E.; Vanham, G. et al. The COVID-19 pandemic: diverse contexts; different epidemics-how and why?. *BMJ global health* **2020**, 5(7), e003098. <a href="https://doi.org/10.1136/bmjgh-2020-003098">https://doi.org/10.1136/bmjgh-2020-003098</a>
- 8. Wong, J.; Goh, Q. Y.; Tan, Z.; Lie, S. A.; Tay, Y. C.; Ng, S. Y. et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. *Canadian journal of anaesthesia* **2020**, 67(6), 732–745. https://doi.org/10.1007/s12630-020-01620-9
- 9. Xiang, Y. T.; Yang, Y.; Li, W.; Zhang, L.; Zhang, Q.; Cheung, T. et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. *Lancet Psychiatry* 2020, 7(3), 228–229. https://doi.org/10.1016/s2215-0366(20)30046-8
- 10. Gautret, P.; Lagier, J. C.; Parola, P.; Hoang, V. T.; Meddeb, L.; Mailhe, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International journal of antimicrobial agents* 2020, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
- 11. Aouissi, H.A.; Ababsa, M.; Gaagai, A. Review of a controversial treatment method in the fight against COVID-19 with the example of Algeria. *Bulletin of the National Research Centre* **2021**, 45(1), 94. <a href="https://doi.org/10.1186/s42269-021-00550-w">https://doi.org/10.1186/s42269-021-00550-w</a>
- 12. Batiha, G. E.; Zayed, M. A.; Awad, A.A.; Shaheen, H. M.; Mustapha, S.; Herrera-Calderon, O. et al. Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19. Frontiers in medicine 2021, 8, 642313. https://doi.org/10.3389/fmed.2021.642313
- 13. Norrie, J. D. Remdesivir for COVID-19: challenges of underpowered studies. *The Lancet* **2020**, 395(10236), 1525–1527. <a href="https://doi.org/10.1016/S0140-6736(20)31023-0">https://doi.org/10.1016/S0140-6736(20)31023-0</a>

579 14. Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C. et al. Remdesivir for the Treatment 580 of Covid-19 - Final Report. *The New England journal of medicine* **2020**, 383(19), 1813–1826. 581 https://doi.org/10.1056/NEJMoa2007764

- 15. Coomes, E. A.; Haghbayan, H. Favipiravir, an antiviral for COVID-19?. The Journal of antimicrobial chemotherapy 2020, 75(7), 2013–2014. https://doi.org/10.1093/jac/dkaa171
  - 16. RECOVERY Collaborative Group; Horby, P.; Lim, W. S.; Emberson, J. R.; Mafham, M.; Bell, J. L. et al. Dexamethasone in Hospitalized Patients with Covid-19. *The New England journal of medicine* **2021**, 384(8), 693–704. <a href="https://doi.org/10.1056/NEJMoa2021436">https://doi.org/10.1056/NEJMoa2021436</a>
  - 17. Gendrot, M.; Duflot, I.; Boxberger, M.; Delandre, O.; Jardot, P.; Le Bideau, et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. *International journal of infectious diseases* **2020**, 99, 437–440. <a href="https://doi.org/10.1016/j.ijid.2020.08.032">https://doi.org/10.1016/j.ijid.2020.08.032</a>
  - 18. Schmith, V. D.; Zhou, J. J.; Lohmer, L. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clinical pharmacology and therapeutics 2020, 108(4), 762–765. https://doi.org/10.1002/cpt.1889
  - 19. Roussel, R.; Darmon, P.; Pichelin, M.; Goronflot, T.; Abouleka, Y.; Ait Bachir, L. et al. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. *Diabetes, obesity & metabolism* **2021**, 23(5), 1162–1172. https://doi.org/10.1111/dom.14324
  - 20. Thanh Le, T.; Andreadakis, Z.; Kumar, A.; Gómez Román, R.; Tollefsen, S.; Saville, M. et al. The COVID-19 vaccine development landscape. *Nature reviews. Drug discovery* **2020**, 19(5), 305–306. https://doi.org/10.1038/d41573-020-00073-5
  - 21. Graham, B.S. Rapid COVID-19 vaccine development. *Science* **2020**, 368(6494), 945–946. https://doi.org/10.1126/science.abb8923
  - 22. Mathieu, E.; Ritchie, H.; Ortiz-Ospina, E.; Roser, M.; Hasell, J.; Appel, C. et al. A global database of COVID-19 vaccinations. *Nature human behavior* **2021**, 5(7), 947–953. https://doi.org/10.1038/s41562-021-01122-8
  - 23. Shay, D. K.; Gee, J.; Su, J. R.; Myers, T. R.; Marquez, P.; Liu, R. et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine United States, March-April 2021. MMWR. Morbidity and mortality weekly report 2021, 70(18), 680–684. https://doi.org/10.15585/mmwr.mm7018e2
  - 24. Livingston, E. H.; Malani, P. N.; Creech, C. B. The Johnson & Johnson Vaccine for COVID-19. *JAMA* **2021**, 325(15), 1575-1575. <a href="https://doi.org/10.1001/jama.2021.2927">https://doi.org/10.1001/jama.2021.2927</a>
  - 25. Oliver, S. E.; Gargano, J. W.; Marin, M.; Wallace, M.; Curran, K. G.; Chamberland, M. et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine United States, December 2020. MMWR. Morbidity and mortality weekly report 2020, 69(50), 1922–1924. <a href="https://doi.org/10.15585/mmwr.mm6950e2">https://doi.org/10.15585/mmwr.mm6950e2</a>
  - 26. Britton, A.; Jacobs Slifka, K.M.; Edens, C.; Nanduri, S.A.; Bart, S.M.; Shang, N. et al. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks Connecticut, December 2020-February 2021. MMWR. Morbidity and mortality weekly report 2021, 70(11), 396–401. <a href="https://doi.org/10.15585/mmwr.mm7011e3">https://doi.org/10.15585/mmwr.mm7011e3</a>
  - 27. Mahase, E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. *BMJ: British Medical Journal* **2020**, 371. https://doi.org/10.1136/bmj.m4471
  - 28. Callaway, E. COVID vaccine excitement builds as Moderna reports third positive result. *Nature* **2020**, 587(7834), 337–338. <a href="https://doi.org/10.1038/d41586-020-03248-7">https://doi.org/10.1038/d41586-020-03248-7</a>
  - 29. Vogel, G.; Kupferschmidt, K. Side effect worry grows for AstraZeneca vaccine. *Science* **2021**, 372(6537), 14–15. <a href="https://doi.org/10.1126/science.372.6537.14">https://doi.org/10.1126/science.372.6537.14</a>
  - 30. Knoll, M.D.; Wonodi, C. Oxford-AstraZeneca COVID-19 vaccine efficacy. *The Lancet* **2021**, 397(10269), 72–74. <a href="https://doi.org/10.1016/S0140-6736(20)32623-4">https://doi.org/10.1016/S0140-6736(20)32623-4</a>
  - 31. Logunov, D.Y.; Dolzhikova, I.V.; Shcheblyakov, D.V.; Tukhvatulin, A. I.; Zubkova, O.V.; Dzharullaeva, A.S. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *The Lancet* **2021**, 397(10275), 671–681. https://doi.org/10.1016/S0140-6736(21)00234-8
  - 32. Jones, I.; Roy, P. Sputnik V COVID-19 vaccine candidate appears safe and effective. *The Lancet* **2021**, 397(10275), 642–643. https://doi.org/10.1016/S0140-6736(21)00191-4
- 33. Mallapaty, S. China COVID vaccine reports mixed results what does that mean for the pandemic?, *Nature* **2021**, Advance online publication. <a href="https://doi.org/10.1038/d41586-021-00094-z">https://doi.org/10.1038/d41586-021-00094-z</a>
  - 34. Forni, G.; Mantovani, A.; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome COVID-19 vaccines: where we stand and challenges ahead. *Cell death and differentiation* **2021**, 28(2), 626–639. <a href="https://doi.org/10.1038/s41418-020-00720-9">https://doi.org/10.1038/s41418-020-00720-9</a>
  - 35. Cohen, J. China's vaccine gambit. Science 2020, 370(6522), 1263–1267. https://doi.org/10.1126/science.370.6522.1263
  - 36. Ella, R.; Vadrevu, K.M.; Jogdand, H.; Prasad, S.; Reddy, S.; Sarangi, V. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *The Lancet Infectious diseases* **2021**, 21(5), 637–646. <a href="https://doi.org/10.1016/S1473-3099(20)30942-7">https://doi.org/10.1016/S1473-3099(20)30942-7</a>
- 637 37. Palacios, R.; Patiño, E. G.; de Oliveira Piorelli, R.; Conde, M.; Batista, A. P.; Zeng, G. et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. *Trials* **2020**, 21(1), 853. https://doi.org/10.1186/s13063-020-04775-4

- 38. Jara, A.; Undurraga, E.A.; González, C.; Paredes, F.; Fontecilla, T.; Jara, G. et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *The New England journal of medicine* **2021**, NEJMoa2107715. <a href="https://doi.org/10.1056/NEJMoa2107715">https://doi.org/10.1056/NEJMoa2107715</a>
- 644 39. Lopez Bernal, J.; Andrews, N.; Gower, C.; Gallagher, E.; Simmons, R.; Thelwall, S. et al. Effectiveness of Covid-19 Vac-645 cines against the B.1.617.2 (Delta) Variant. The New England journal of medicine 2021, NEJMoa2108891. 646 https://doi.org/10.1056/NEJMoa2108891
- 40. Zhao, X.; Li, D.; Ruan, W.; Zhang, R.; Zheng, A.; Qiao, S.; Zheng, X.; Zhao, Y.; Chen, Z.; Dai, L. Han, P.; Gao, G.F. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents. bioRxiv, 2021.

654

- 41. Mahase, E. Covid-19: Vaccine brands can be mixed in "extremely rare occasions," says Public Health England. *BMJ (Clinical research ed.)* **2021**, 372, n12. <a href="https://doi.org/10.1136/bmj.n12">https://doi.org/10.1136/bmj.n12</a>
- 42. Aouissi HA. Algeria's preparedness for Omicron variant and for the fourth wave of COVID-19. *Glob Health Med.* **2021**, 3(6), 413-414. https://doi.org/10.35772/ghm.2021.01117
- 43. Balanzá-Martínez, V.; Kapczinski, F.; de Azevedo Cardoso, T.; Atienza-Carbonell, B.; Rosa, A.R.; Mota, J.C. et al. The assessment of lifestyle changes during the COVID-19 pandemic using a multidimensional scale. *Revista de psiquiatria y salud mental* **2021**, 14(1), 16–26. <a href="https://doi.org/10.1016/j.rpsm.2020.07.003">https://doi.org/10.1016/j.rpsm.2020.07.003</a>
- 44. Garre-Olmo, J.; Turró-Garriga, O.; Martí-Lluch, R.; Zacarías-Pons, L.; Alves-Cabratosa, L.; Serrano-Sarbosa, D. et al. Changes in lifestyle resulting from confinement due to COVID-19 and depressive symptomatology: A cross-sectional a population-based study. *Comprehensive psychiatry* **2021**, 104, 152214. https://doi.org/10.1016/j.comppsych.2020.152214
- 45. Geldsetzer, P. Knowledge and Perceptions of COVID-19 Among the General Public in the United States and the United Kingdom: A Cross-sectional Online Survey. *Annals of internal medicine* **2020**, 173(2), 157–160. https://doi.org/10.7326/M20-0912
- 46. Agarwal, A.; Ranjan, P.; Rohilla, P.; Saikaustubh, Y.; Sahu, A.; Dwivedi, S.N. et al. Development and validation of a questionnaire to assess preventive practices against COVID-19 pandemic in the general population. *Preventive medicine reports* **2021**, 22, 101339. <a href="https://doi.org/10.1016/j.pmedr.2021.101339">https://doi.org/10.1016/j.pmedr.2021.101339</a>
- 47. Pan, K.Y.; Kok, A.; Eikelenboom, M.; Horsfall, M.; Jörg, F.; Luteijn, R.A. et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. *The lancet. Psychiatry* **2021**, 8(2), 121–129. https://doi.org/10.1016/S2215-0366(20)30491-0
- 48. Chopra, S.; Ranjan, P.; Malhotra, A.; Sahu, A.; Dwivedi, S.N.; Baitha, U. et al. Development and validation of a question-naire to evaluate the impact of COVID-19 on lifestyle-related behaviours: eating habits, activity and sleep behaviour. *Public health nutrition* **2021**, 24(6), 1275–1290. https://doi.org/10.1017/S1368980020004656
- 49. Yan, S.; Xu, R.; Stratton, T.D.; Kavcic, V.; Luo, D.; Hou, F. et al. Sex differences and psychological stress: responses to the COVID-19 pandemic in China. *BMC public health* **2021**, 21(1), 79. <a href="https://doi.org/10.1186/s12889-020-10085-w">https://doi.org/10.1186/s12889-020-10085-w</a>
- 50. Kobayashi, L.C.; O'Shea, B.Q.; Kler, J.S.; Nishimura, R.; Palavicino-Maggio, C.B.; Eastman, M.R. et al. Cohort profile: the COVID-19 Coping Study, a longitudinal mixed-methods study of middle-aged and older adults' mental health and well-being during the COVID-19 pandemic in the USA. *BMJ open* **2021**, 11(2), e044965. https://doi.org/10.1136/bmjopen-2020-044965
- 51. Moulin, F.; El-Aarbaoui, T.; Bustamante, J.; Héron, M.; Mary-Krause, M.; Rouquette, A. et al. Risk and protective factors related to children's symptoms of emotional difficulties and hyperactivity/inattention during the COVID-19-related lockdown in France: results from a community sample. *European child & adolescent psychiatry* **2021**, 1–12. <a href="https://doi.org/10.1007/s00787-021-01752-3">https://doi.org/10.1007/s00787-021-01752-3</a>
- 52. Zhou, F.; You, C.; Zhang, X.; Qian, K.; Hou, Y.; Gao, Y. et al. Epidemiological Characteristics and Factors Associated with Critical Time Intervals of COVID-19 in Eighteen Provinces, China: A Retrospective Study. *International journal of infectious diseases* 2021, 102, 123–131. <a href="https://doi.org/10.1016/j.ijid.2020.09.1487">https://doi.org/10.1016/j.ijid.2020.09.1487</a>
- 53. Wolff, D.; Nee, S.; Hickey, N.S.; Marschollek, M. Risk factors for Covid-19 severity and fatality: a structured literature review. *Infection* **2021**, 49(1), 15–28. <a href="https://doi.org/10.1007/s15010-020-01509-1">https://doi.org/10.1007/s15010-020-01509-1</a>
- 54. Islam, F.M.A.; Walton, A. Tobacco smoking and use of smokeless tobacco and their association with psychological distress and other factors in a rural district in Bangladesh: A cross-sectional study. *Journal of environmental and public health* **2019**, 1424592. <a href="https://doi.org/10.1155/2019/1424592">https://doi.org/10.1155/2019/1424592</a>
- 55. Yingst, J.M.; Krebs, N.M.; Bordner, C.R.; Hobkirk, A.L.; Allen, S.I.; Foulds, J. Tobacco Use Changes and Perceived Health Risks among Current Tobacco Users during the COVID-19 Pandemic. *International Journal of Environmental Research and Public* Health 2021, 18(4), 1795. <a href="https://doi.org/10.3390/ijerph18041795">https://doi.org/10.3390/ijerph18041795</a>
- 56. Kim, L.; Garg, S.; O'Halloran, A.; Whitaker, M.; Pham, H.; Anderson, E. J. et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clinical infectious diseases 2021, 72(9), e206–e214. https://doi.org/10.1093/cid/ciaa1012
- 57. Ko, J. Y.; Danielson, M.L.; Town, M.; Derado, G.; Greenlund, K.J.; Kirley, P.D. et al. Risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization: COVID-19–associated hospitalization surveillance network and behavioral risk factor surveillance system. *Clinical Infectious Diseases* 2021, 72(11), e695-e703. https://doi.org/10.1093/cid/ciaa1419
- 58. Berlin, I.; Thomas, D.; Le Faou, A.L; Cornuz, J. COVID-19 and smoking. *Nicotine and Tobacco Research* **2020**, 22(9), 1650-1652 https://doi.org/10.1093/ntr/ntaa059

59. Mistry, S.K.; Ali, A.M.; Rahman, M.A.; Yadav, U.N.; Gupta, B. et al. Changes in Tobacco Use Patterns during COVID-19 and Their Correlates among Older Adults in Bangladesh. *International Journal of Environmental Research and Public Health* 2021, 18(4), 1779. <a href="https://doi.org/10.3390/ijerph18041779">https://doi.org/10.3390/ijerph18041779</a>

- 60. Simou, E.; Britton, J.; Leonardi-Bee, J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. *BMJ open* **2018**, 8(8), e022344. <a href="https://doi.org/10.1136/bmjopen-2018-022344">https://doi.org/10.1136/bmjopen-2018-022344</a>
- 61. Abuga, K.; Nyamweya, N. Alcohol-Based Hand Sanitizers in COVID-19 Prevention: A Multidimensional Perspective. *Pharmacy* **2021**, 9(1), 64. <a href="https://doi.org/10.3390/pharmacy9010064">https://doi.org/10.3390/pharmacy9010064</a>
- 62. Da, B. L.; Im, G. Y.; Schiano, T. D. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease. *Hepatology* **2020**, 72(3), 1102–1108. <a href="https://doi.org/10.1002/hep.31307">https://doi.org/10.1002/hep.31307</a>
- 63. Testino, G. Are Patients With Alcohol Use Disorders at Increased Risk for Covid-19 Infection?. *Alcohol and alcoholism* **2020**, 55(4), 344–346. <a href="https://doi.org/10.1093/alcalc/agaa037">https://doi.org/10.1093/alcalc/agaa037</a>
- 64. Heidari, M.; Sayfouri, N. COVID-19 and Alcohol Poisoning: A Fatal Competition. *Disaster Medicine and Public Health Preparedness* **2021**, 1-3. https://doi.org/10.1017/dmp.2021.89
- 65. Hassanian-Moghaddam, H.; Pajoumand, A.; Dadgar, S. M.; Shadnia, S. H. Prognostic factors in methanol poisoning. *Human & experimental toxicology* **2007**, 26(7), 583–586. <a href="https://doi.org/10.1177/0960327106080077">https://doi.org/10.1177/0960327106080077</a>
- 66. Lassen, M.C.H.; Skaarup, K.G.; Sengeløv, M.; Iversen, K.; Ulrik, C.S.; Jensen, J.U.S et al. Alcohol Consumption and the Risk of Acute Respiratory Distress Syndrome in COVID-19. *Annals of the American Thoracic Society* **2020**, 18(6), 1074–1076. https://doi.org/10.1513/AnnalsATS.202008-988RL
- 67. Wong, C-M.; Lai, H-K.; OU, C-Q.; Ho, S.Y.; Chan, K.P; Thach, T.Q. et al. Is Exercise Protective Against Influenza-Associated Mortality? *PloS one* **2008**, 2; 3: e2108. <a href="https://doi.org/10.1371/journal.pone.0002108">https://doi.org/10.1371/journal.pone.0002108</a>
- 68. Lowder, T.; Padgett, D.A.; Woods, J.A. Moderate exercise protects mice from death due to influenza virus. *Brain Behav Immun.* 2005, 19: 377-380. https://doi.org/10.1016/j.bbi.2005.04.002
- 69. Zimmer, P.; Schenk, A.; Kieven, M.; Holthaus, M.; Lehmann, J.; Lövenich, L. et al. Exercise induced alterations in NK-cell cytotoxicity methodological issues and future perspectives. *Exercise immunology review* **2017**, 23, 66–81.
- 70. Wackerhage, H.; Everett, R.; Krüger, K.; Murgia, M.; Simon, P.; Gehlert, S. et al. Sport, exercise and COVID-19, the disease caused by the SARS-CoV-2 coronavirus. *Dtsch. Z. Sportmed* **2020**, 71(5), e1-12. <a href="https://doi.org/10.5960/dzsm.2020.441">https://doi.org/10.5960/dzsm.2020.441</a>
- 71. Narici, M.; Vito, G.; Franchi, M.; Paoli, A.; Moro, T.; Marcolin, G. et al. Impact of sedentarism due to the COVID-19 home confinement on neuromuscular, cardiovascular and metabolic health: Physiological and pathophysiological implications and recommendations for physical and nutritional countermeasures. *European journal of sport science* **2021**, 21(4), 614–635. <a href="https://doi.org/10.1080/17461391.2020.1761076">https://doi.org/10.1080/17461391.2020.1761076</a>
- 72. Hammami, A.; Harrabi, B.; Mohr, M.; Krustrup, P. Physical activity and coronavirus disease 2019 (COVID-19): specific recommendations for home-based physical training, *Managing Sport and Leisure* 2020, https://doi.org/10.1080/23750472.2020.1757494
- 73. Polero, P.; Rebollo-Seco, C.; Adsuar, J. C.; Pérez-Gómez, J.; Rojo-Ramos, J.; Manzano-Redondo, F., et al. Physical Activity Recommendations during COVID-19: Narrative Review. *International Journal of Environmental Research and Public Health* **2020**, 18(1), 65. <a href="https://doi.org/10.3390/ijerph18010065">https://doi.org/10.3390/ijerph18010065</a>
- 74. Li, J.; Wang, X.; Chen, J.; Cai, Y.; Deng, A.; Yang, M. Association between ABO blood groups and risk of SARS-CoV-2 pneumonia. *British journal of haematology* **2020**, 190(1), 24–27. <a href="https://doi.org/10.1111/bjh.16797">https://doi.org/10.1111/bjh.16797</a>
- 75. Anderson, J.L.; May, H.T.; Knight, S.; Bair, T. L.; Muhlestein, J.B.; Knowlton, K.U. et al. Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population. *JAMA Network Open* **2021**, 4(4), e217429-e217429. https://doi.org/10.1001/jamanetworkopen.2021.7429
- 76. Goel, R.; Bloch, E.M.; Pirenne, F.; Al-Riyami, A.Z.; Crowe, E.; Dau, L. et al. ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 working group. *Vox sanguinis* **2021**. <a href="https://doi.org/10.1111/vox.13076">https://doi.org/10.1111/vox.13076</a>
- 77. Miotto, M.; Di Rienzo, L.; Gosti, G.; Milanetti, E.; Ruocco, G. Does blood type affect the COVID-19 infection pattern?. *PloS one* **2021**, 16(5): e0251535. <a href="https://doi.org/10.1371/journal.pone.0251535">https://doi.org/10.1371/journal.pone.0251535</a>
- 78. Bhopal, R.S. Migration, ethnicity, race, and health in multicultural societies. Oxford University Press: Oxford. UK. 2014
- 79. Yancy, C.W. COVID-19 and African Americans. *JAMA* **2020**, May 19;323(19):1891-1892. https://doi.org/10.1001/jama.2020.6548
- 80. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E. et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020, 584(7821), 430–436. https://doi.org/10.1038/s41586-020-2521-4
- 81. Katikireddi, S.V.; Lal, S.; Carrol, E.D.; Niedzwiedz, C.L.; Khunti, K.; Dundas, R. et al. Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. *J Epidemiol Community Health* **2021**, jech-2020-216061 <a href="https://doi.org/10.1136/jech-2020-216061">https://doi.org/10.1136/jech-2020-216061</a>
- 82. Sze, S.; Pan, D.; Nevill, C.R.; Gray, L.J.; Martin, C.A.; Nazareth, J.; Minhas, J.S.; Divall, P.; Khunti, K.; Abrams, K.R.; Nellums, L.B.; Pareek, M. Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. *EClinical Medicine* **2020**, 29, 100630. <a href="https://doi.org/10.1016/j.eclinm.2020.100630">https://doi.org/10.1016/j.eclinm.2020.100630</a>
- 83. Vist, G.E.; Arentz-Hansen, E.H.; Vedøy, T.F.; Spilker, R.A.C.S.; Hafstad, E.V.; Giske, L. Incidence and severe outcomes from COVID-19 among immigrant and minority ethnic groups and among groups of different socio-economic status: A systematic review. 2021. Url: <a href="https://hdl.handle.net/11250/2754026">https://hdl.handle.net/11250/2754026</a>
- Nacher, M.; Rousseau, C.; Succo, T.; Andrieu, A.; Gaillet, M.; Michaud, C. et al. The Epidemiology of COVID 19 in the Amazon and the Guianas: Similarities, Differences, and International Comparisons. *Frontiers in public health* **2021**, 9, 586299. <a href="https://doi.org/10.3389/fpubh.2021.586299">https://doi.org/10.3389/fpubh.2021.586299</a>

85. Dehingia, N.; Raj, A. Sex differences in COVID-19 case fatality: do we know enough?. *The Lancet Global Health* **2021**, 9(1), e14-e15. https://doi.org/10.1016/S2214-109X(20)30464-2

- 86. Judah, G.; Aunger, R.; Schmidt, W.P.; Michie, S.; Granger, S.; Curtis, V. Experimental pretesting of hand-washing interventions in a natural setting. *American journal of public health* **2009**, 99(S2), S405-S411. https://doi.org/10.1038/s41467-020-19741-6
- 87. Peckham, H.; de Gruijter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R. et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nature communications* **2020**, 11(1), 6317. <a href="https://doi.org/10.1038/s41467-020-19741-6">https://doi.org/10.1038/s41467-020-19741-6</a>
- 88. Raimondi, F.; Novelli, L.; Ghirardi, A.; Russo, F.M.; Pellegrini, D.; Biza, R. et al. Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study. *BMC pulmonary medicine* **2021**, 21(1), 96. <a href="https://doi.org/10.1186/s12890-021-01455-0">https://doi.org/10.1186/s12890-021-01455-0</a>
- 89. Joe, W.; Kumar, A.; Rajpal, S.; Mishra, U.; Subramanian, S.V. Equal risk, unequal burden? Gender differentials in COVID-19 mortality in India. *J Glob Health Sci* **2020**, 2(1):e17. <a href="https://doi.org/10.35500/jghs.2020.2.e17">https://doi.org/10.35500/jghs.2020.2.e17</a>
- 90. Bhopal, S.S.; Bhopal, R. Sex differential in COVID-19 mortality varies markedly by age. *The Lancet* **2020**. 396(10250), 532–533. https://doi.org/10.1016/S0140-6736(20)31748-7
- 91. Wang, Y.; Pang, S.C.; Yang, Y. A potential association between immunosenescence and high COVID-19 related mortality among elderly patients with cardiovascular diseases. *Immun Ageing* **2021**, 18, 25 <a href="https://doi.org/10.1186/s12979-021-00234-z">https://doi.org/10.1186/s12979-021-00234-z</a>
- 92. Porcheddu, R.; Serra, C.; Kelvin, D.; Kelvin, N.; Rubino, S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China, *J Infect Dev Ctries* 2020, 14:125-128. https://doi.org/10.3855/jidc.12600
- 93. Bonanad, C.; Garcia-Blas, S.; Tarazona-Santabalbina, F.; Sanchis, J.; Bertomeu-González, V.; Facila, L. et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. *Journal of the American Medical Directors Association* 2020, 21(7), 915-918. https://doi.org/10.1016/j.jamda.2020.05.045
- 94. Aouissi, H.A.; Belhaouchet, I. What about rheumatic diseases and COVID-19?. New microbes and new infections 2021, 41, 100846. https://doi.org/10.1016/j.nmni.2021.100846
- 95. Cox, L.S.; Bellantuono, I.; Lord, J.M.; Sapey, E.; Mannick, J.B.; Partridge, L. et al. Tackling Immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. *The Lancet Healthy Longevity* **2020**, 1(2), e55-e57. https://doi.org/10.1016/S2666-7568(20)30011-8
- 96. Genebat, M.; Tarancón-Díez, L.; De Pablo-Bernal, R.; Calderón, A.; Muñoz-Fernández, M.Á.; Leal, M. Coronavirus Disease (COVID-19): a perspective from immunosenescence. *Aging and disease* **2021**, 12(1), 3. <a href="https://doi.org/10.14336/AD.2020.0831">https://doi.org/10.14336/AD.2020.0831</a>
- 97. Pietrobon, A.J.; Teixeira, F.M.E.; Sato, M.N. Immunosenescence and inflammaging: Risk factors of severe covid-19 in older people. *Frontiers in Immunology* **2020**, 11. <a href="https://doi.org/10.3389/fimmu.2020.579220">https://doi.org/10.3389/fimmu.2020.579220</a>
- 98. Sasson, I. Age and COVID-19 mortality: A comparison of Gompertz doubling time across countries and causes of death. Demographic Research 2021, 44, 379-396. https://doi.org/10.4054/DemRes.2021.44.16
- 99. Lim, M. Q.; Kumaran, E.A.; Tan, H.C.; Lye, D.C.; Leo, Y.S.; Ooi, E.E. et al. Cross-reactivity and anti-viral function of dengue capsid and NS3-specific memory T cells toward Zika virus. *Frontiers in immunology* **2018**, 9, 2225. <a href="https://doi.org/10.3389/fimmu.2018.02225">https://doi.org/10.3389/fimmu.2018.02225</a>
- 100. Zhang, Q.; Bastard, P.; Liu, Z.; Le Pen, J.; Moncada-Velez, M.; Chen, J. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* **2020**, 370(6515). <a href="https://doi.org/10.1126/science.abd4570">https://doi.org/10.1126/science.abd4570</a>
- 101. Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.H.; Zhang, Y. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* **2020**, 370(6515). <a href="https://doi.org/10.1126/science.abd4585">https://doi.org/10.1126/science.abd4585</a>
- 102. Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.; Hafezi, M.; Chia, A. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **2020**, 584(7821), 457–462. <a href="https://doi.org/10.1038/s41586-020-2550-z">https://doi.org/10.1038/s41586-020-2550-z</a>
- 103. Van Damme, W.; Dahake, R.; Van de Pas, R.; Vanham, G.; Assefa, Y. COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?. *Medical hypotheses* 2021, 146, 110431. <a href="https://doi.org/10.1016/j.mehy.2020.110431">https://doi.org/10.1016/j.mehy.2020.110431</a>
- 104. Fakhroo, A.D.; Al Thani, A.A.; Yassine, H.M. Markers Associated with COVID-19 Susceptibility, Resistance, and Severity. *Viruses* **2020**, 13(1), 45. <a href="https://doi.org/10.3390/v13010045">https://doi.org/10.3390/v13010045</a>
- 105. Oshio, T.; Kan, M. Educational level as a predictor of the incidences of non-communicable diseases among middle-aged Japanese: a hazards-model analysis. *BMC public health* **2019**, 19(1), 852. <a href="https://doi.org/10.1186/s12889-019-7182-6">https://doi.org/10.1186/s12889-019-7182-6</a>
- 106. Concepción-Zavaleta, M. J.; Coronado-Arroyo, J.C.; Zavaleta-Gutiérrez, F.E.; Concepción-Urteaga, L. A. Does level of education influence mortality of SARS-CoV-2 in a developing country? *International Journal of Epidemiology* **2020**, 49(6), 2091–2093. https://doi.org/10.1093/jie/dyaa193
- 107. Lakshmi Priyadarsini, S.; Suresh, M. Factors influencing the epidemiological characteristics of pandemic COVID 19: A TISM approach. *International Journal of Healthcare Management* **2020**, 13(2), 89-98. <a href="https://doi.org/10.1080/20479700.2020.1755804">https://doi.org/10.1080/20479700.2020.1755804</a>
- 108. Millett, G. A.; Jones, A.T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C. et al. Assessing differential impacts of COVID-19 on Black communities. *Annals of Epidemiology* **2020**, 47, 37–44. <a href="https://doi.org/10.1016/j.annepidem.2020.05.003">https://doi.org/10.1016/j.annepidem.2020.05.003</a>
- 109. Margolis, R. Educational differences in healthy behavior changes and adherence among middle-aged Americans. *Journal of Health and Social Behavior* **2013**, 54(3), 353–368. <a href="https://doi.org/10.1177/0022146513489312">https://doi.org/10.1177/0022146513489312</a>

110. Friis, K.; Lasgaard, M.; Rowlands, G.; Osborne, R.H.; Maindal, H.T. Health literacy mediates the relationship between educational attainment and health behavior: A Danish population-based study. *Journal of Health Communication* 2016, 21(sup2), 54–60. https://doi.org/10.1080/10810730.2016.1201175

- 111. Upshaw, T.L.; Brown, C.; Smith, R.; Perri, M.; Ziegler, C.; Pinto, A.D. Social determinants of COVID-19 incidence and outcomes: A rapid review. *PloS one* **2021**, 16(3), e0248336. <a href="https://doi.org/10.1371/journal.pone.0248336">https://doi.org/10.1371/journal.pone.0248336</a>
- 112. Lee, J.; Lim, H.; Allen, J.; Choi, G. Effects of Learning Attitudes and COVID-19 Risk Perception on Poor Academic Performance among Middle School Students. *Sustainability* **2021**, 13(10):5541. https://doi.org/10.3390/su13105541
- 113. Aouissi, HA. Hydroxychloroquine in the fight against covid-19-Hydroxychloroquine dans la lutte contre la covid-19-. *Maghr. J. Pure & Appl. Sci.* **2020**, 6 (2) 65-71. <a href="https://doi.org/10.48383/IMIST.PRSM/mjpas-v6i2.22513">https://doi.org/10.48383/IMIST.PRSM/mjpas-v6i2.22513</a>
- 114. An, B.Y.; Tang, S.Y. Lessons from COVID-19 responses in East Asia: Institutional infrastructure and enduring policy instruments. *The American Review of Public Administration* **2020**, 50(6-7), 790-800. <a href="https://doi.org/10.1177/0275074020943707">https://doi.org/10.1177/0275074020943707</a>
- 115. Kraemer, M.; Yang, C.H.; Gutierrez, B.; Wu, C.H.; Klein, B.; Pigott, D.M. et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. *MedRxiv* **2020**, 2020.03.02.20026708. https://doi.org/10.1101/2020.03.02.20026708
- 116. Ababsa, M.; Aouissi, H.A. Current state of the coronavirus (Covid-19) in Algeria. *J Commun Med Health Care* **2020**, 5(1):1036. https://doi.org/10.26420/jcommunitymedhealthcare.2020.1036
- 117. McKenzie, G.; Adams, B. A country comparison of place-based activity response to COVID-19 policies. *Applied geography* **2020**, 125, 102363. <a href="https://doi.org/10.1016/j.apgeog.2020.102363">https://doi.org/10.1016/j.apgeog.2020.102363</a>
- 118. Centers for Disease Control and Prevention. Protect yourself: coronavirus disease (COVID-19). Retrieved February 4, 2021, from <a href="https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html">https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html</a>
- 119. Combessie, J. C. La méthode de Sociologie, Chapter 4. Sondages, échantillons. Ed. La découverte. Coll. « Reperes», Paris, France. **2007**, pp 45-54.
- 120. Arora, C.; Sinha, B.; Malhotra, A.; Ranjan, P. Development and validation of health education tools and evaluation questionnaires for improving patient care in lifestyle related diseases. *J Clin Diagn Res* **2017**, 11(5):JE06. https://doi.org/10.7860/JCDR/2017/28197.9946
- 121. Reethesh, S.R; Ranjan, P.; Arora, C.; Kaloiya, G.S.; Vikram, N.K.; Dwivedi, S.N. et al. Development and validation of a questionnaire assessing knowledge, attitude, and practices about obesity among obese individuals. *Indian J Endocr Metab* **2019**, 23(1):102. <a href="https://doi.org/10.4103/ijem.IJEM">https://doi.org/10.4103/ijem.IJEM</a> 487 18
- 122. Pereltsvaig, A. Languages of the World: An Introduction, 2nd edition, Cambridge: Cambridge University Press.UK, **2017**. <a href="https://doi.org/10.1017/9781316758854">https://doi.org/10.1017/9781316758854</a>
- 123. Collett, D. Modelling Binary Data. 2nd edition. Chapman & Hall/CRC: London, UK, pp. 93. <a href="https://doi.org/10.1201/b16654">https://doi.org/10.1201/b16654</a>
- 124. Subedi, D.; Pantha, S.; Subedi, S.; Gautam, A.; Gaire, A.; Sapkota, D.; Sapkota, S.; Kandel, M.; Parajuli, A.; Ghimire, H.; Ghimire, S.; Devkota, J.; Dhakal, S. Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal. *Vaccines* 2021, 9, 1448. <a href="https://doi.org/10.3390/vaccines9121448">https://doi.org/10.3390/vaccines9121448</a>
- 125. Shah, A. S.; Gribben, C.; Bishop, J.; Hanlon, P.; Caldwell, D.; Wood, R. et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *MedRxiv* 2021. https://doi.org/10.1101/2021.03.11.21253275
- 126. Lipsitch, M.; Kahn, R. Interpreting vaccine efficacy trial results for infection and transmission. *MedRxiv* 2021, 2021.02.25.21252415. https://doi.org/10.1101/2021.02.25.21252415
- 127. Meier, K.; Glatz, T.; Guijt, M.C.; Piccininni, M.; Van der Meulen, M.; Atmar, K. et al. Public perspectives on protective measures during the COVID-19 pandemic in the Netherlands, Germany and Italy: A survey study. *PloS one* **2020**, 15(8), e0236917. <a href="https://doi.org/10.1371/journal.pone.0236917">https://doi.org/10.1371/journal.pone.0236917</a>
- 128. Abdulateef, D. S.; Rahman, H. S.; Salih, J. M.; Osman, S. M.; Mahmood, T.A.; Omer, S.; Ahmed, R.A. COVID-19 severity in relation to sociodemographics and vitamin D use. *Open medicine* **2021**, 16(1), 591–609. <a href="https://doi.org/10.1515/med-2021-0273">https://doi.org/10.1515/med-2021-0273</a>
- 129. Sohn, M.; Koo, B.K.; Yoon, H.I.; Song, K. H.; Kim, E.S.; Kim, H.B.; Lim, S. Impact of COVID-19 and Associated Preventive Measures on Cardiometabolic Risk Factors in South Korea. *Journal of obesity & metabolic syndrome* **2021**, 30(3), 248–260. <a href="https://doi.org/10.7570/jomes21046">https://doi.org/10.7570/jomes21046</a>
- 130. Rana, M. S.; Usman, M.; Alam, M. M.; Ikram, A.; Salman, M.; Zaidi, S.; Umair, M.; Qadir, M. Impact of COVID-19 preventive measures on other infectious and non-infectious respiratory diseases in Pakistan. *The Journal of infection* **2021**, 82(5), 31–32. https://doi.org/10.1016/j.jinf.2021.01.018
- 131. Sugimura, M.; Chimed-Ochir, O.; Yumiya, Y.; Ohge, H.; Shime, N.; Sakaguchi, T.; Tanaka, J.; Takafuta, T.; Mimori, M.; Kuwabara, M.; Asahara, T.; Kishita, E.; Kubo, T. The Association between Wearing a Mask and COVID-19. *Int. J. Environ. Res. Public Health* **2021**, 18, 9131. <a href="https://doi.org/10.3390/ijerph18179131">https://doi.org/10.3390/ijerph18179131</a>
- 132. Ramasamy, M.N.; Minassian, A.M.; Ewer, K.J.; Flaxman, A.L.; Folegatti, P.M.; Owens, D.R.; Voysey, M.; Aley, P.K.; Angus, B.; Babbage, G.; Belij-Rammerstorfer, S.; Berry, L.; Bibi, S.; Bittaye, M.; Cathie, K.; Chappell, H.; Charlton, S.; Cicconi, P.; Clutterbuck, E.A.; Colin-Jones, R.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* 2021, 396(10267), 1979–1993. https://doi.org/10.1016/S0140-6736(20)32466-1

133. O'Driscoll, M.; Ribeiro Dos Santos, G.; Wang, L.; Cummings, D.; Azman, A.S.; Paireau, J.; Fontanet, A.; Cauchemez, S.; Salje, H. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature*, **2021**, 590(7844), 140–145. https://doi.org/10.1038/s41586-020-2918-0

- 134. Li, J.; Liao, X.; Zhou, Y.; Wang, L.; Yang, H.; Zhang, W.; Zhang, Z.; Kang, Y. Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. *Shock* **2021**, 56(2), 215–228. <a href="https://doi.org/10.1097/SHK.000000000001738">https://doi.org/10.1097/SHK.000000000000001738</a>
- 135. Gao, Y.D.; Ding, M.; Dong, X.; Zhang, J.J.; Kursat Azkur, A.; Azkur, D.; Gan, H.; Sun, Y.L.; Fu, W.; Li, W.; Liang, H.L.; Cao, Y.Y.; Yan, Q.; Cao, C.; Gao, H.Y.; Brüggen, M.C.; Van de Veen, W.; Sokolowska, M.; Akdis, M.; Akdis, C.A. Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy* 2021, 76(2), 428–455. <a href="https://doi.org/10.1111/all.14657">https://doi.org/10.1111/all.14657</a>
- 136. Abbasi-Oshaghi, E.; Mirzaei, F.; Khodadadi, I. Alcohol Misuse May Increase the Severity of COVID-19 Infections. *Disaster medicine and public health preparedness* **2020**, 1–2. <a href="https://doi.org/10.1017/dmp.2020.452">https://doi.org/10.1017/dmp.2020.452</a>
- 137. Hikida, S.; Morioka, S.; Fujii, N.; Tajima, T.; Terayama, Y.; Sugiura, Y. et al. A single-center descriptive study of untraced sources of infection among new cases of coronavirus disease in Tokyo, Japan. *Global Health & Medicine* **2021**, 2021.01092. https://doi.org/10.35772/ghm.2021.01092
- 138. González-Reimers, E.; Santolaria-Fernández, F.; Martín-González, M.C.; Fernández-Rodríguez, C.M.; Quintero-Platt, G. Alcoholism: a systemic proinflammatory condition. *World journal of gastroenterology* **2014**, 20(40), 14660–14671. https://doi.org/10.3748/wjg.v20.i40.14660
- 139. Dai, M.; Tao, L.; Chen, Z.; Tian, Z.; Guo, X.; Allen-Gipson, D.S. et al. Influence of Cigarettes and Alcohol on the Severity and Death of COVID-19: A Multicenter Retrospective Study in Wuhan, China. *Frontiers in physiology* **2020**, 11, 588553. https://doi.org/10.3389/fphys.2020.588553
- 141. Saengow, U.; Assanangkornchai, S.; Casswell, S. Alcohol: a probable risk factor of COVID-19 severity. *Addiction* **2021**, 116(1), 204–205. https://doi.org/10.1111/add.15194
- 142. Calina, D.; Hartung, T.; Mardare, I.; Mitroi, M.; Poulas, K.; Tsatsakis, A. et al. COVID-19 pandemic and alcohol consumption: Impacts and interconnections. *Toxicology reports* **2021**, 8, 529–535. <a href="https://doi.org/10.1016/j.toxrep.2021.03.005">https://doi.org/10.1016/j.toxrep.2021.03.005</a>
- 143. Reddy, R.K.; Charles, W.N.; Sklavounos, A.; Dutt, A.; Seed, P.T.; Khajuria, A. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. *Journal of medical virology* **2021**, 93(2), 1045–1056. https://doi.org/10.1002/jmv.26389
- 144. Izcovich, A.; Ragusa, M.A.; Tortosa, F.; Lavena Marzio, M.A.; Agnoletti, C.; Bengolea, A.; Ceirano, A.; Espinosa, F.; Saavedra, E.; Sanguine, V.; Tassara, A.; Cid, C.; Catalano, H.N.; Agarwal, A.; Foroutan, F.; Rada, G. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. *PloS one* **2020**, 15(11), e0241955. https://doi.org/10.1371/journal.pone.0241955
- 145. Simons, D.; Shahab, L.; Brown, J.; Perski, O. The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). *Addiction* **2021**, 116(6), 1319–1368. <a href="https://doi.org/10.1111/add.15276">https://doi.org/10.1111/add.15276</a>
- 146. Rozhnova, G.; Van Dorp, C.H.; Bruijning-Verhagen, P.; Bootsma, M.; Van de Wijgert, J.; Bonten, M. et al. Model-based evaluation of school- and non-school-related measures to control the COVID-19 pandemic. *Nature communications* **2021**, 12(1), 1614. <a href="https://doi.org/10.1038/s41467-021-21899-6">https://doi.org/10.1038/s41467-021-21899-6</a>
- 147. Krishnaratne, S.; Pfadenhauer, L.M.; Coenen, M.; Geffert, K.; Jung-Sievers, C.; Klinger, C. et al. Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review. *The Cochrane database of systematic reviews* **2020**, 12, CD013812. <a href="https://doi.org/10.1002/14651858.CD013812">https://doi.org/10.1002/14651858.CD013812</a>
- 148. Zhao, Y.; Liang, W.; Luo, Y.; Chen, Y.; Liang, P.; Zhong, R. et al. Personal protective equipment protecting healthcare workers in the Chinese epicentre of COVID-19. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020, 26(12), 1716–1718. https://doi.org/10.1016/j.cmi.2020.07.029
- 149. Canet-Vélez, O.; Botigué, T.; Lavedán Santamaría, A.; Masot, O.; Cemeli, T.; Roca, J. The perception of training and professional development according to nursing students as health workers during COVID-19: A qualitative study. *Nurse education in practice* **2021**, 53, 103072. <a href="https://doi.org/10.1016/j.nepr.2021.103072">https://doi.org/10.1016/j.nepr.2021.103072</a>
- 150. Thomson, S. Achievement at school and socioeconomic background-an educational perspective. *NPJ science of learning* **2018**, 3, 5. <a href="https://doi.org/10.1038/s41539-018-0022-0">https://doi.org/10.1038/s41539-018-0022-0</a>
- 151. Destin, M.; Hanselman, P.; Buontempo, J.; Tipton, E.; Yeager, D.S. Do Student Mindsets Differ by Socioeconomic Status and Explain Disparities in Academic Achievement in the United States?. *AERA open* **2019**, 5(3). https://doi.org/10.1177/2332858419857706
- 152. Schultze, J. L.; Aschenbrenner, A.C. COVID-19 and the human innate immune system. *Cell* **2021**, 184(7), 1671–1692. <a href="https://doi.org/10.1016/j.cell.2021.02.029">https://doi.org/10.1016/j.cell.2021.02.029</a>
- 153. Chumakov, K.; Avidan, M.S.; Benn, C.S.; Bertozzi, S.M.; Blatt, L.; Chang, A.Y et al. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. *Proceedings of the National Academy of Sciences of the United States of America* **2021**, 118(21), e2101718118. <a href="https://doi.org/10.1073/pnas.2101718118">https://doi.org/10.1073/pnas.2101718118</a>
- 154. Kasuga, Y.; Zhu, B.; Jang, K.J.; Yoo, J.S. Innate immune sensing of coronavirus and viral evasion strategies. *Experimental & molecular medicine* **2021**, 53(5), 723–736. <a href="https://doi.org/10.1038/s12276-021-00602-1">https://doi.org/10.1038/s12276-021-00602-1</a>
- 946 155. Franza, L.; Cianci, R. Pollution, Inflammation, and Vaccines: A Complex Crosstalk. *International journal of environmental research and public health* **2021**, 18(12), 6330. <a href="https://doi.org/10.3390/ijerph18126330">https://doi.org/10.3390/ijerph18126330</a>

948 156. Jaber, R.M.; Mafrachi, B.; Al-Ani, A.; Shkara, M. Awareness and perception of COVID-19 among the general population: 949 A Middle Eastern survey. *PloS one* **2021**, 16(4), e0250461. <a href="https://doi.org/10.1371/journal.pone.0250461">https://doi.org/10.1371/journal.pone.0250461</a>

- 157. Bazaid, A.S.; Aldarhami, A.; Binsaleh, N.K.; Sherwani, S.; Althomali, O.W. Knowledge and practice of personal protective measures during the COVID-19 pandemic: A cross-sectional study in Saudi Arabia. *PloS one* **2020**, 15(12), e0243695. <a href="https://doi.org/10.1371/journal.pone.0243695">https://doi.org/10.1371/journal.pone.0243695</a>
- 158. Binsaleh, N.K.; Bazaid, A.S.; Aldarhami, A.; Sherwani, S.; Althomali, O.W. Awareness and Practice of COVID-19 Precautionary Measures Among Healthcare Professionals in Saudi Arabia. *Journal of multidisciplinary healthcare* **2021**, 14, 1553–1560. <a href="https://doi.org/10.2147/JMDH.S317908">https://doi.org/10.2147/JMDH.S317908</a>
- 159. Medrano, M.; Cadenas-Sanchez, C.; Oses, M.; Arenaza, L.; Amasene, M.; Labayen, I. Changes in lifestyle behaviours during the COVID-19 confinement in Spanish children: A longitudinal analysis from the MUGI project. *Pediatric obesity* **2021**, 16(4), e12731. <a href="https://doi.org/10.1111/jipo.12731">https://doi.org/10.1111/jipo.12731</a>
- 160. He, M.; Xian, Y.; Lv, X.; He, J.; Ren, Y. Changes in Body Weight, Physical Activity, and Lifestyle During the Semi-lockdown Period After the Outbreak of COVID-19 in China: An Online Survey. *Disaster medicine and public health preparedness* 2020, 1–6. https://doi.org/10.1017/dmp.2020.237
- 161. Aldhuwayhi, S.; Mallineni, S.K.; Sakhamuri, S.; Thakare, A.A.; Mallineni, S.; Sajja, R. et al. Covid-19 Knowledge and Perceptions Among Dental Specialists: A Cross-Sectional Online Questionnaire Survey. *Risk management and healthcare policy* **2021**, 14, 2851–2861. https://doi.org/10.2147/RMHP.S306880
- 162. Chopra, S.; Ranjan, P.; Malhotra, A.; Sahu, A.; Dwivedi, S.N.; Baitha, U. et al. Development and validation of a question-naire to evaluate the impact of COVID-19 on lifestyle-related behaviours: eating habits, activity and sleep behaviour. *Public health nutrition* **2021**, 24(6), 1275–1290. https://doi.org/10.1017/S1368980020004656
- 163. Komal, A.; Noreen, M.; Akhtar, J.; Imran, M.; Jamal, M.; Atif, M. et al. Analyses of ABO blood groups with susceptibility and symptomatic variations of COVID-19 infection, a questionnaire-based survey. *APMIS: acta pathologica, microbiologica, et immunologica Scandinavica* **2021**, 10.1111/apm.13169. https://doi.org/10.1111/apm.13169
- 164. Coccia, M. Factors determining the diffusion of COVID-19 and suggested strategy to prevent future accelerated viral infectivity similar to COVID. *The Science of the total environment* **2020**, 729, 138474. https://doi.org/10.1016/j.scitotenv.2020.138474
- 165. Lim, Y.K.; Kweon, O.J.; Kim, H. R.; Kim, T.H.; Lee, M.K. The impact of environmental variables on the spread of COVID-19 in the Republic of Korea. *Scientific reports* **2021**, 11(1), 5977. https://doi.org/10.1038/s41598-021-85493-y
- 166. Azuma, K.; Yanagi, U.; Kagi, N.; Kim, H.; Ogata, M.; Hayashi, M. Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. *Environmental health and preventive medicine* 2020, 25(1), 66. <a href="https://doi.org/10.1186/s12199-020-00904-2">https://doi.org/10.1186/s12199-020-00904-2</a>
- 167. Greenhalgh, T.; Jimenez, J.L.; Prather, K.A.; Tufekci, Z.; Fisman, D.; Schooley, R. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *The Lancet* 2021, 397(10285), 1603–1605. <a href="https://doi.org/10.1016/S0140-6736(21)00869-2">https://doi.org/10.1016/S0140-6736(21)00869-2</a>
- 168. Huang, C.; Huang, L.; Wang, Y.; Li, X.; Ren, L.; Gu, X. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet* **2021**, 397(10270), 220–232. <a href="https://doi.org/10.1016/S0140-6736(20)32656-8">https://doi.org/10.1016/S0140-6736(20)32656-8</a>
- 169. Patel, M.; Chaubey, A.K.; Pittman, C.U.; Jr, Mlsna, T.; Mohan, D. Coronavirus (SARS-CoV-2) in the environment: Occurrence, persistence, analysis in aquatic systems and possible management. *The Science of the total environment* **2021**, 765, 142698. https://doi.org/10.1016/j.scitotenv.2020.142698